
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Assessment of PBC Pruritus From the ITCH‐E Study: Quality of Life, Productivity, and Treatment Experiences - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE530D818AEEA283050D81004D2811FD.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Liver International">
<meta name="citation_title" content="Assessment of PBC Pruritus From the ITCH‐E Study: Quality of Life, Productivity, and Treatment Experiences">
<meta name="citation_author" content="Cynthia Levy">
<meta name="citation_author_institution" content="Schiff Center for Liver Diseases, University of Miami, Miami, Florida, USA">
<meta name="citation_author" content="Zobair M Younossi">
<meta name="citation_author_institution" content="The Global Liver Council, Washington, DC, USA">
<meta name="citation_author_institution" content="Beatty Liver and Obesity Research, Inova Health System, Falls Church, Virginia, USA">
<meta name="citation_author" content="Marlyn J Mayo">
<meta name="citation_author_institution" content="Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA">
<meta name="citation_author" content="Andreas E Kremer">
<meta name="citation_author_institution" content="Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland">
<meta name="citation_author" content="Jennifer Pate">
<meta name="citation_author_institution" content="Independent Researcher, Sugar Land, Texas, USA">
<meta name="citation_author" content="Jonathan Ieyoub">
<meta name="citation_author_institution" content="CymaBay Therapeutics, Fremont, California, USA">
<meta name="citation_author" content="Rebekah Zincavage">
<meta name="citation_author_institution" content="Stratevi, Santa Monica, California, USA">
<meta name="citation_author" content="Brad Padilla">
<meta name="citation_author_institution" content="Stratevi, Santa Monica, California, USA">
<meta name="citation_author" content="Diane Ito">
<meta name="citation_author_institution" content="Stratevi, Santa Monica, California, USA">
<meta name="citation_author" content="C Fiorella Murillo Perez">
<meta name="citation_author_institution" content="Gilead Sciences, Foster City, California, USA">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="45">
<meta name="citation_issue" content="9">
<meta name="citation_firstpage" content="e70276">
<meta name="citation_doi" content="10.1111/liv.70276">
<meta name="citation_pmid" content="40847640">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/pdf/LIV-45-0.pdf">
<meta name="description" content="This US‐based study assessed the impact of pruritus on health‐related quality of life (HRQoL) and treatment experiences of people with primary biliary cholangitis (PBC). Patients with PBC were recruited from a physician panel and patient advocacy ...">
<meta name="og:title" content="Assessment of PBC Pruritus From the ITCH‐E Study: Quality of Life, Productivity, and Treatment Experiences">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="This US‐based study assessed the impact of pruritus on health‐related quality of life (HRQoL) and treatment experiences of people with primary biliary cholangitis (PBC). Patients with PBC were recruited from a physician panel and patient advocacy ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374225">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1111/liv.70276"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/LIV-45-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374225%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374225/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374225/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1111/liv.70276" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Liver Int</button></div>. 2025 Aug 23;45(9):e70276. doi: <a href="https://doi.org/10.1111/liv.70276" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1111/liv.70276</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Liver%20Int%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver%20Int%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Liver%20Int%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Liver%20Int%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Assessment of PBC Pruritus From the ITCH‐E Study: Quality of Life, Productivity, and Treatment Experiences</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Levy%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Cynthia Levy</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Cynthia Levy</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Schiff Center for Liver Diseases, University of Miami, Miami, Florida, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Levy%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cynthia Levy</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Younossi%20ZM%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Zobair M Younossi</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Zobair M Younossi</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>The Global Liver Council, Washington, DC, USA</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Beatty Liver and Obesity Research, Inova Health System, Falls Church, Virginia, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Younossi%20ZM%22%5BAuthor%5D" class="usa-link"><span class="name western">Zobair M Younossi</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mayo%20MJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Marlyn J Mayo</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Marlyn J Mayo</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mayo%20MJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Marlyn J Mayo</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kremer%20AE%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Andreas E Kremer</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Andreas E Kremer</span></h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kremer%20AE%22%5BAuthor%5D" class="usa-link"><span class="name western">Andreas E Kremer</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pate%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Jennifer Pate</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Jennifer Pate</span></h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>Independent Researcher, Sugar Land, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pate%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jennifer Pate</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ieyoub%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Jonathan Ieyoub</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Jonathan Ieyoub</span></h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>CymaBay Therapeutics, Fremont, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ieyoub%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jonathan Ieyoub</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zincavage%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Rebekah Zincavage</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Rebekah Zincavage</span></h3>
<div class="p">
<sup>
<sup>8</sup>
</sup>Stratevi, Santa Monica, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zincavage%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Rebekah Zincavage</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Padilla%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Brad Padilla</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Brad Padilla</span></h3>
<div class="p">
<sup>
<sup>8</sup>
</sup>Stratevi, Santa Monica, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Padilla%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Brad Padilla</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ito%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Diane Ito</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Diane Ito</span></h3>
<div class="p">
<sup>
<sup>8</sup>
</sup>Stratevi, Santa Monica, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ito%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Diane Ito</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Perez%20CFM%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">C Fiorella Murillo Perez</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">C Fiorella Murillo Perez</span></h3>
<div class="p">
<sup>
<sup>9</sup>
</sup>Gilead Sciences, Foster City, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Perez%20CFM%22%5BAuthor%5D" class="usa-link"><span class="name western">C Fiorella Murillo Perez</span></a>
</div>
</div>
<sup>9</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="liv70276-aff-0001">
<sup>
<sup>1</sup>
</sup>Schiff Center for Liver Diseases, University of Miami, Miami, Florida, USA</div>
<div id="liv70276-aff-0002">
<sup>
<sup>2</sup>
</sup>The Global Liver Council, Washington, DC, USA</div>
<div id="liv70276-aff-0003">
<sup>
<sup>3</sup>
</sup>Beatty Liver and Obesity Research, Inova Health System, Falls Church, Virginia, USA</div>
<div id="liv70276-aff-0004">
<sup>
<sup>4</sup>
</sup>Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA</div>
<div id="liv70276-aff-0005">
<sup>
<sup>5</sup>
</sup>Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland</div>
<div id="liv70276-aff-0006">
<sup>
<sup>6</sup>
</sup>Independent Researcher, Sugar Land, Texas, USA</div>
<div id="liv70276-aff-0007">
<sup>
<sup>7</sup>
</sup>CymaBay Therapeutics, Fremont, California, USA</div>
<div id="liv70276-aff-0008">
<sup>
<sup>8</sup>
</sup>Stratevi, Santa Monica, California, USA</div>
<div id="liv70276-aff-0009">
<sup>
<sup>9</sup>
</sup>Gilead Sciences, Foster City, California, USA</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Cynthia Levy (<span>clevy@med.miami.edu</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jun 30; Received 2025 Feb 13; Accepted 2025 Jul 30; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Liver International</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374225  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40847640/" class="usa-link">40847640</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<section id="liv70276-sec-0001"><h3 class="pmc_sec_title">Background &amp; Aims</h3>
<p>This US‐based study assessed the impact of pruritus on health‐related quality of life (HRQoL) and treatment experiences of people with primary biliary cholangitis (PBC).</p></section><section id="liv70276-sec-0002"><h3 class="pmc_sec_title">Methods</h3>
<p>Patients with PBC were recruited from a physician panel and patient advocacy group. Participants were grouped by the Pruritus Numerical Rating Scale (NRS): No/Mild Pruritus (NMP, NRS &lt; 4) and Moderate/Severe Pruritus (MSP, NRS ≥ 4). Participants completed the 5‐D Itch, PBC‐40, EQ‐5D‐5L, Chronic Liver Disease Questionnaire (CLDQ‐PBC), Work Productivity and Activity Impairment (WPAI), and Functional Assessment of Chronic Illness Therapy – Fatigue Scale, Version 4 (FACIT‐Fatigue) questionnaires, and PBC treatment experiences questions. Differences were analysed using regression models for confounders. An MSP group subset responded to voice questions.</p></section><section id="liv70276-sec-0003"><h3 class="pmc_sec_title">Results</h3>
<p>The sample included 40 NMP and 50 MSP participants, with 85% and 80% females, respectively. The MSP group reported significantly worse outcomes on 5‐D Itch, EQ‐5D Index, PBC‐40 (all domains besides Emotional), FACIT‐Fatigue, and CLDQ‐PBC total scores compared to the NMP group (all <em>p</em> &lt; 0.05). The MSP group reported significantly greater activity impairment due to PBC (57%) than the NMP group (36%; <em>p</em> &lt; 0.001). The MSP group had a lower employment rate (42%) than the NMP group (53%). Fewer than 25% of the MSP group were receiving itch treatment.</p></section><section id="liv70276-sec-0004"><h3 class="pmc_sec_title">Conclusions</h3>
<p>Individuals with PBC and pruritus report limited pruritus treatment use and minimal itch relief. Those with moderate/severe pruritus experience a greater HRQoL burden and reduced activity compared to those with mild/no pruritus. This highlights the need for effective treatments that ameliorate pruritus in patients with PBC.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> autoimmune liver disease, cholestatic pruritus, patient voice, patient‐reported outcomes, PBC, quality of life</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="liv70276-blkfxd-0001"><h2 class="obj_head">Summary.</h2>
<ul id="liv70276-list-0001" class="list" style="list-style-type:disc"><li id="liv70276-li-0001"><p>There is limited real‐world evidence on the impact of pruritus in primary biliary cholangitis (PBC) in the US. Our study shows that moderate‐to‐severe pruritus significantly worsens the quality of life for PBC patients; yet fewer than 25% receive treatments for pruritus due to their limited efficacy. This highlights the significant unmet need for better therapies to manage pruritus in PBC.</p></li></ul></section><section id="sec5"><h3>Abbreviations</h3>
<dl class="def-list" id="liv70276-dl-0001">
<dt id="liv70276-li-0002">CLDQ</dt>
<dd id="liv70276-li-0003"><p>Chronic Liver Disease Questionnaire</p></dd>
<dt id="liv70276-li-0004">EQ‐5D‐5L</dt>
<dd id="liv70276-li-0005"><p>EuroQol 5‐Dimension 5‐Level</p></dd>
<dt id="liv70276-li-0006">FACIT‐Fatigue</dt>
<dd id="liv70276-li-0007"><p>Functional Assessment of Chronic Illness Therapy – Fatigue Scale</p></dd>
<dt id="liv70276-li-0008">FDA</dt>
<dd id="liv70276-li-0009"><p>Food and Drug Administration</p></dd>
<dt id="liv70276-li-0010">HCC</dt>
<dd id="liv70276-li-0011"><p>hepatocellular carcinoma</p></dd>
<dt id="liv70276-li-0012">HRQoL</dt>
<dd id="liv70276-li-0013"><p>health‐related quality of life</p></dd>
<dt id="liv70276-li-0014">MSP</dt>
<dd id="liv70276-li-0015"><p>moderate/severe pruritus</p></dd>
<dt id="liv70276-li-0016">NMP</dt>
<dd id="liv70276-li-0017"><p>no/mild pruritus</p></dd>
<dt id="liv70276-li-0018">NRS</dt>
<dd id="liv70276-li-0019"><p>numerical rating scale</p></dd>
<dt id="liv70276-li-0020">OCA</dt>
<dd id="liv70276-li-0021"><p>obeticholic acid</p></dd>
<dt id="liv70276-li-0022">PBC</dt>
<dd id="liv70276-li-0023"><p>primary biliary cholangitis</p></dd>
<dt id="liv70276-li-0024">PRO</dt>
<dd id="liv70276-li-0025"><p>patient‐reported outcome</p></dd>
<dt id="liv70276-li-0026">SD</dt>
<dd id="liv70276-li-0027"><p>standard deviation</p></dd>
<dt id="liv70276-li-0028">UDCA</dt>
<dd id="liv70276-li-0029"><p>ursodeoxycholic acid</p></dd>
<dt id="liv70276-li-0030">US</dt>
<dd id="liv70276-li-0031"><p>United States</p></dd>
<dt id="liv70276-li-0032">WPAI</dt>
<dd id="liv70276-li-0033"><p>Work Productivity and Activity Impairment</p></dd>
</dl></section><section id="liv70276-sec-0008"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Primary biliary cholangitis (PBC) is a progressive, chronic autoimmune liver disease characterised by immuno‐inflammatory destruction of small bile ducts (cholestasis) and the buildup of harmful bile acids [<a href="#liv70276-bib-0001" class="usa-link" aria-describedby="liv70276-bib-0001">1</a>, <a href="#liv70276-bib-0002" class="usa-link" aria-describedby="liv70276-bib-0002">2</a>, <a href="#liv70276-bib-0003" class="usa-link" aria-describedby="liv70276-bib-0003">3</a>]. If left untreated, PBC can lead to advanced fibrosis, decompensated cirrhosis, hepatocellular carcinoma (HCC), liver failure, liver transplantation, and premature death [<a href="#liv70276-bib-0004" class="usa-link" aria-describedby="liv70276-bib-0004">4</a>, <a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>]. The estimated prevalence of PBC in the United States (US) is 39.2 per 100 000 individuals [<a href="#liv70276-bib-0004" class="usa-link" aria-describedby="liv70276-bib-0004">4</a>, <a href="#liv70276-bib-0006" class="usa-link" aria-describedby="liv70276-bib-0006">6</a>], with estimates for the number of individuals in the US with PBC reaching as high as 130 000 [<a href="#liv70276-bib-0007" class="usa-link" aria-describedby="liv70276-bib-0007">7</a>].</p>
<p>Although patients with PBC may not exhibit symptoms at the time of diagnosis, most will eventually develop symptoms, typically 2–4 years after diagnosis [<a href="#liv70276-bib-0008" class="usa-link" aria-describedby="liv70276-bib-0008">8</a>]. The most common symptoms of PBC are cholestatic pruritus, sicca complex, and fatigue [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>]. Patients with PBC may also report abdominal discomfort, joint pain, and bone pain [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>]. Up to 70% of patients with PBC experience cholestatic pruritus during the course of their disease, and more than one‐third have moderate‐to‐severe itch [<a href="#liv70276-bib-0009" class="usa-link" aria-describedby="liv70276-bib-0009">9</a>, <a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>]. Severe cholestatic pruritus can be unbearable, leading to sleep deprivation, social isolation, and can trigger suicidal ideation [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>, <a href="#liv70276-bib-0011" class="usa-link" aria-describedby="liv70276-bib-0011">11</a>]. In extreme cases, pruritus can justify liver transplantation, even in the absence of cirrhosis or decompensated liver disease [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>, <a href="#liv70276-bib-0011" class="usa-link" aria-describedby="liv70276-bib-0011">11</a>]. Pruritus in PBC patients typically fluctuates over time and is generally not directly correlated with disease severity [<a href="#liv70276-bib-0012" class="usa-link" aria-describedby="liv70276-bib-0012">12</a>].</p>
<p>The impact of cholestatic pruritus on patients with PBC, particularly the stress and burden it causes, has not been extensively studied [<a href="#liv70276-bib-0013" class="usa-link" aria-describedby="liv70276-bib-0013">13</a>]. A US study utilising a longitudinal PBC cohort found that patients with clinically significant pruritus, defined as ≥ 7 on the PBC‐40 Itch domain, experienced significantly (<em>p</em> &lt; 0.05) lower health‐related quality of life (HRQoL), as measured by the PBC‐40, the 5‐D Pruritus Scale (5‐D Itch Scale), and the PROMIS Fatigue Survey, compared to those with no or mild pruritus [<a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>]. PBC impacts multiple domains of patients' lives, including HRQoL, itch, and sleep. However, the effects of pruritus on other areas, such as work productivity, have been less thoroughly studied.</p>
<p>Our current study provides a comprehensive evaluation of HRQoL in PBC patients experiencing pruritus, utilising multiple validated instruments. These include PBC‐specific measures like the PBC‐40 and the Chronic Liver Disease Questionnaire (CLDQ)‐PBC [<a href="#liv70276-bib-0014" class="usa-link" aria-describedby="liv70276-bib-0014">14</a>, <a href="#liv70276-bib-0015" class="usa-link" aria-describedby="liv70276-bib-0015">15</a>, <a href="#liv70276-bib-0016" class="usa-link" aria-describedby="liv70276-bib-0016">16</a>]. The Work Productivity and Activity Impairment (WPAI) Questionnaire, infrequently used in previous PBC studies, was included to offer new insights into how pruritus impacts work productivity and daily activities. Additionally, voice data provided qualitative insights into the painful nature of pruritus and its negative effects on emotional health and productivity, complementing quantitative assessments to enhance understanding of the patient experience.</p>
<p>As of early 2024, the standard treatment for PBC starts with ursodeoxycholic acid (UDCA) as the first‐line therapy [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>, <a href="#liv70276-bib-0008" class="usa-link" aria-describedby="liv70276-bib-0008">8</a>]. For patients who do not respond adequately or are intolerant to UDCA, obeticholic acid (OCA) is used as a second‐line treatment [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>, <a href="#liv70276-bib-0008" class="usa-link" aria-describedby="liv70276-bib-0008">8</a>]; however, OCA is contraindicated in patients with decompensated cirrhosis or compensated cirrhosis with evidence of portal hypertension due to the risk of serious liver injury, including liver failure and the need for liver transplantation [<a href="#liv70276-bib-0017" class="usa-link" aria-describedby="liv70276-bib-0017">17</a>]. In May 2021, the US Food and Drug Administration (FDA) issued a communication restricting the use of OCA in patients with PBC and advanced cirrhosis for these safety reasons [<a href="#liv70276-bib-0018" class="usa-link" aria-describedby="liv70276-bib-0018">18</a>]. In December 2024, the FDA reported additional cases of serious liver injury in PBC patients treated with OCA who did not have cirrhosis. That communication advised healthcare providers and patients of this new safety concern and emphasised the importance of frequent liver tests to detect worsening function and guide timely discontinuation of OCA [<a href="#liv70276-bib-0019" class="usa-link" aria-describedby="liv70276-bib-0019">19</a>]. The effectiveness of these therapies has been shown through changes in surrogate biochemical markers (e.g., alkaline phosphatase) [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>, <a href="#liv70276-bib-0020" class="usa-link" aria-describedby="liv70276-bib-0020">20</a>]. In addition to pharmacological approaches, non‐pharmacological solutions include cool morning showers, light therapy, and choosing breathable clothing [<a href="#liv70276-bib-0021" class="usa-link" aria-describedby="liv70276-bib-0021">21</a>].</p>
<p>Despite well‐established treatment guidelines and clinical evidence supporting the efficacy of UDCA and OCA, patients with PBC may discontinue treatment due to intolerance, incomplete response to therapy, or side effects [<a href="#liv70276-bib-0022" class="usa-link" aria-describedby="liv70276-bib-0022">22</a>]. Pruritus has been frequently cited as a reason for OCA discontinuation [<a href="#liv70276-bib-0023" class="usa-link" aria-describedby="liv70276-bib-0023">23</a>, <a href="#liv70276-bib-0024" class="usa-link" aria-describedby="liv70276-bib-0024">24</a>, <a href="#liv70276-bib-0025" class="usa-link" aria-describedby="liv70276-bib-0025">25</a>].</p>
<p>A real‐world study using a longitudinal cohort to evaluate the impact of pruritus on patients' quality of life found that pruritus in PBC patients is often undertreated, with only about half (51%) of patients with clinically significant pruritus receiving treatment for their pruritus [<a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>]. Notably, this study did not provide reasons for why patients discontinued their previous treatments [<a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>]. While some research has explored treatment patterns, there remains a need for further investigation into discontinuation patterns of PBC treatments and therapies for PBC‐related pruritus among US patients [<a href="#liv70276-bib-0023" class="usa-link" aria-describedby="liv70276-bib-0023">23</a>].</p>
<p>Given the limited research in this area in the US, obtaining patients' perspectives regarding the burden and unmet treatment needs of PBC‐related cholestatic pruritus is critical to raising awareness of their experiences, HRQoL, and psychosocial needs. Capturing the patient's voice may further illuminate the challenges they face, providing valuable insights that could guide more effective treatment and management strategies. Thus, the purpose of this observational, mixed methods study was to evaluate perceptions of pruritus and its impact on quality of life and well‐being among people living with PBC in the US. Additionally, this study examined patients' experiences with PBC treatments, including their overall perceptions, treatment patterns, and reasons for discontinuation.</p></section><section id="liv70276-sec-0009"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="liv70276-sec-0010"><h3 class="pmc_sec_title">2.1. Participant Selection</h3>
<p>US participants were recruited (1) from the PBCers Organisation, the largest PBC online support group in the US, and (2) through physician panels that included patients with a physician‐confirmed PBC diagnosis. Participants first completed a screening survey to determine their eligibility for this study. Individuals who met the study eligibility criteria were asked to provide their informed consent electronically and then complete a questionnaire via their smartphones or computers. The study was approved by the WCG Institutional Review Board (IRB tracking ID: 20235194).</p>
<p>Patients with a diagnosis of PBC were eligible to participate if they were aged ≥ 18 years, living in the US, self‐reported that they were currently taking an FDA‐approved treatment for PBC (at the time of the study, either UDCA or OCA), and provided study informed consent. Patients were ineligible to participate if they were not taking/receiving either UDCA and/or OCA, were a current employee of CymaBay Therapeutics (a wholly owned subsidiary of Gilead Sciences Inc.) or had an immediate family member who was a current CymaBay Therapeutics employee, were unable to read or understand English, had neither a mobile device nor access to a computer, or were currently enrolled in a clinical trial for a PBC treatment at the time of the study. Patients taking UDCA, OCA, or both were eligible regardless of concurrent therapies (e.g., fibrates).</p>
<p>Based on the Pruritus NRS completed during screening, participants were categorised into two groups: (1) patients with a Pruritus NRS score of 0–3 were allocated to the No/Mild Pruritus (NMP) group; and (2) patients with a Pruritus NRS score of 4–10 were allocated to the Moderate/Severe Pruritus (MSP) group.</p>
<p>A subset of participants from the MSP group was also asked to respond to qualitative voice questions by calling into an automated voice response system. This qualitative voice questionnaire was open to the first 25 participants from the MSP group who agreed to complete the voice questions. Eligible individuals could participate in the voice response portion of the study by calling in and responding to each of the prompts by talking into their phone. They responded independently without a moderator present.</p></section><section id="liv70276-sec-0011"><h3 class="pmc_sec_title">2.2. Power Calculation and Sample Size</h3>
<p>A power calculation was conducted to determine the adequate sample size needed to test for differences between patients with moderate/severe pruritus (i.e., the MSP group) and patients without or with mild pruritus (i.e., the NMP group). Differences in HRQoL scores (PBC‐40 Itch domain scores) between PBC patients with and without pruritus from prior literature were used to estimate the expected difference between patients stratified into the NMP and MSP groups [<a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>, <a href="#liv70276-bib-0026" class="usa-link" aria-describedby="liv70276-bib-0026">26</a>]. An estimate of the minimum sample size needed to test for pre‐specified group differences at 80% power and <em>α</em> = 0.05 was calculated, resulting in a final target sample size of 90 patients.</p></section><section id="liv70276-sec-0012"><h3 class="pmc_sec_title">2.3. Study Variables</h3>
<p>All participants were asked about their demographics, diagnostic and treatment characteristics, pruritus severity, disease‐specific quality of life, health utility, fatigue, activity impairment, and work productivity.</p>
<p>Two patient‐reported outcome (PRO) measures were administered to gather data on pruritus. The Pruritus NRS is a validated, single‐item PRO measure that assesses the severity of pruritus on a 0–10 scale [<a href="#liv70276-bib-0027" class="usa-link" aria-describedby="liv70276-bib-0027">27</a>, <a href="#liv70276-bib-0028" class="usa-link" aria-describedby="liv70276-bib-0028">28</a>]. The 5‐D Itch Scale is a validated 8‐item PRO assessing various aspects of pruritus, including the duration, degree, direction, disability (related to itching), and distribution (which body parts have been impacted) of pruritus [<a href="#liv70276-bib-0028" class="usa-link" aria-describedby="liv70276-bib-0028">28</a>, <a href="#liv70276-bib-0029" class="usa-link" aria-describedby="liv70276-bib-0029">29</a>].</p>
<p>Several PRO assessments were administered to gather data on the impact of pruritus on patients' quality of life. The PBC‐40 is a validated 40‐item PRO assessing the domains of social, emotional, cognitive function, itch, fatigue, and other symptoms in patients with PBC [<a href="#liv70276-bib-0015" class="usa-link" aria-describedby="liv70276-bib-0015">15</a>, <a href="#liv70276-bib-0028" class="usa-link" aria-describedby="liv70276-bib-0028">28</a>]. The PBC‐specific version of the CLDQ, the CLDQ‐PBC, is a new, validated 35‐item PRO assessing the domains of diet, fatigue, emotional health, itch, sleep, worry, and symptoms in patients with PBC [<a href="#liv70276-bib-0016" class="usa-link" aria-describedby="liv70276-bib-0016">16</a>]. The EuroQol 5‐Dimension 5‐Level (EQ‐5D‐5L) is a validated 6‐item PRO assessing the domains of usual activities, anxiety/depression, pain/discomfort, self‐care, and mobility [<a href="#liv70276-bib-0030" class="usa-link" aria-describedby="liv70276-bib-0030">30</a>]. In addition to the questions assessing these five dimensions, a sixth question includes a visual analogue scale (VAS) whereby participants rate their perceived health [<a href="#liv70276-bib-0030" class="usa-link" aria-describedby="liv70276-bib-0030">30</a>]. The Functional Assessment of Chronic Illness Therapy – Fatigue Scale, Version 4 (FACIT‐Fatigue) is a validated 13‐item PRO assessing fatigue, with higher scores indicating less fatigue and better quality of life [<a href="#liv70276-bib-0031" class="usa-link" aria-describedby="liv70276-bib-0031">31</a>].</p>
<p>The WPAI Questionnaire: General Health (WPAI:GH) V2.0 is a validated, 6‐item PRO measure that assesses the impact of health and symptoms on work productivity and daily activities [<a href="#liv70276-bib-0032" class="usa-link" aria-describedby="liv70276-bib-0032">32</a>, <a href="#liv70276-bib-0033" class="usa-link" aria-describedby="liv70276-bib-0033">33</a>, <a href="#liv70276-bib-0034" class="usa-link" aria-describedby="liv70276-bib-0034">34</a>].</p>
<p>Further details about the score ranges and score interpretation (e.g., a higher score indicates worse quality of life) for each instrument are provided in Table <a href="#liv70276-tbl-0002" class="usa-link">2</a>.</p>
<section class="tw xbox font-sm" id="liv70276-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Unadjusted mean scores for PRO total and domain scores by NMP and MSP groups.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Outcome</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Score interpretation</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Range of scores</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">NMP (<em>N</em> = 40), Mean (SD)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">MSP (<em>N</em> = 50), Mean (SD)</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="5" valign="top" rowspan="1">5‐D itch score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total</td>
<td align="center" valign="top" rowspan="1" colspan="1">Higher score indicates more severe itch and negative impact</td>
<td align="center" valign="top" rowspan="1" colspan="1">5–25</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.7 (2.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">14.4 (3.5)</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">EQ‐5D‐5L score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">EQ‐5D index</td>
<td align="center" rowspan="2" valign="top" colspan="1">Higher scores indicate better quality of life</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.573−1.000</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.63 (0.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">EQ VAS</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–100</td>
<td align="center" valign="top" rowspan="1" colspan="1">64.4 (18.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">60.8 (17.5)</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">PBC‐40 domain scores</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Symptoms</td>
<td align="center" rowspan="6" valign="top" colspan="1">Higher scores indicate worse quality of life</td>
<td align="center" valign="top" rowspan="1" colspan="1">7–35</td>
<td align="center" valign="top" rowspan="1" colspan="1">17.9 (4.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">20.9 (4.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Itch</td>
<td align="center" valign="top" rowspan="1" colspan="1">3–15</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.6 (2.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8.9 (3.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
<td align="center" valign="top" rowspan="1" colspan="1">11–55</td>
<td align="center" valign="top" rowspan="1" colspan="1">30.2 (8.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">37.4 (8.2)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Cognitive</td>
<td align="center" valign="top" rowspan="1" colspan="1">6–30</td>
<td align="center" valign="top" rowspan="1" colspan="1">14.8 (5.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">19.1 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Emotional</td>
<td align="center" valign="top" rowspan="1" colspan="1">3–15</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.2 (3.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10.4 (2.5)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Social</td>
<td align="center" valign="top" rowspan="1" colspan="1">10–50</td>
<td align="center" valign="top" rowspan="1" colspan="1">29.3 (9.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">35.6 (9.3)</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">FACIT‐Fatigue score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total</td>
<td align="center" valign="top" rowspan="1" colspan="1">Higher score indicates less fatigue</td>
<td align="center" valign="top" rowspan="1" colspan="1">0–52</td>
<td align="center" valign="top" rowspan="1" colspan="1">32.2 (10.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">23.9 (12.0)</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">CLDQ‐PBC score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total</td>
<td align="center" valign="top" rowspan="1" colspan="1">Higher score indicates better quality of life</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.9 (1.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.9 (1.4)</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">CLDQ‐PBC domain scores</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Diet</td>
<td align="center" rowspan="7" valign="top" colspan="1">Higher score indicates better quality of life</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.1 (1.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.2 (1.4)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Emotional</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.9 (1.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.1 (1.6)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.6 (1.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.7 (1.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Itch</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.9 (1.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.1 (1.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sleep</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.7 (1.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.8 (1.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Symptoms</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.0 (1.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.1 (1.2)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Worry</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–7</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.3 (1.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.5 (1.9)</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">WPAI scores</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% activity impairment due to PBC</td>
<td align="center" rowspan="4" valign="top" colspan="1">Higher scores indicate greater impairment or productivity loss</td>
<td align="center" valign="top" rowspan="1" colspan="1">0–100</td>
<td align="center" valign="top" rowspan="1" colspan="1">36.3%</td>
<td align="center" valign="top" rowspan="1" colspan="1">56.6%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% work time missed due to PBC (absenteeism)<a href="#liv70276-note-0009" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0–100</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.8%</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.8%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% impairment while working due to PBC (presenteeism)<a href="#liv70276-note-0009" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0–100</td>
<td align="center" valign="top" rowspan="1" colspan="1">32.4%</td>
<td align="center" valign="top" rowspan="1" colspan="1">46.5%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% overall work impairment due to PBC<a href="#liv70276-note-0009" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0–100</td>
<td align="center" valign="top" rowspan="1" colspan="1">35.2%</td>
<td align="center" valign="top" rowspan="1" colspan="1">49.7%</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70276-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70276-note-0008"><p>Abbreviations: 5‐D Itch Scale, 5‐D Pruritus Scale; CLDQ, Chronic Liver Disease Questionnaire; EQ‐5D‐5L, EuroQol 5‐Dimension 5‐Level; FACIT‐Fatigue, Functional Assessment of Chronic Illness Therapy – Fatigue Scale; MSP, moderate/severe pruritus; NMP, no/mild pruritus; PBC, primary biliary cholangitis; SD, standard deviation; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment Questionnaire.</p></div>
<div class="fn" id="liv70276-note-0009">
<sup>
<sup>a</sup>
</sup><p class="display-inline">WPAI scores (except for the activity impairment score) were calculated only for participants who indicated they were currently employed and provided complete and interpretable WPAI data (NMP: <em>n</em> = 21; MSP: <em>n</em> = 17). WPAI scores were excluded for four participants in the MSP group due to responses that were nonsensical and rendered the data uninterpretable.</p>
</div>
</div></section><p>Eight voice‐response questions inquired about PBC symptoms and the effects of PBC on daily life, with a particular focus on pruritus (referred to as “itch due to PBC” for participant understanding). These questions asked participants in the MSP group to describe pruritus and examine the effects of itching on HRQoL, emotional well‐being, and its physical, social, and financial impacts. The automated voice response system asked specific questions about the impact of itch, descriptors of this impact, treatment experiences, and the anticipated effect of improved treatments on their life.</p></section><section id="liv70276-sec-0013"><h3 class="pmc_sec_title">2.4. Data Analysis</h3>
<p>Descriptive statistics were used to analyse all variables in the study for both groups: NMP and MSP groups. Continuous variables were summarised using mean, standard deviation (SD), minimum, median, and maximum. Additional metrics for PRO scores included the 25th percentile, 75th percentile, interquartile range, and 95% confidence interval of the median. Categorical variables were reported as percentages and counts.</p>
<p>Differences in PRO scores between NMP and MSP groups were analysed using multivariable regression models, adjusting for age, gender, ethnicity, insurance, and treatment with UDCA and OCA. Due to the limited sample size of only seven patients receiving fibrates, the statistical model did not include adjustments for fibrate use. All analyses were conducted with either Microsoft Excel or R 4.4.0.</p>
<p>Voice data were analysed qualitatively through content analysis to identify salient themes. Representative patient quotes were highlighted and grouped by theme/topic.</p></section></section><section id="liv70276-sec-0014"><h2 class="pmc_sec_title">3. Results</h2>
<section id="liv70276-sec-0015"><h3 class="pmc_sec_title">3.1. Participant Characteristics</h3>
<p>A total of 159 individuals were recruited and completed the eligibility screener, of whom 122 (77%) met study eligibility criteria, and 90 (57%) participants completed the study (Figure <a href="#liv70276-fig-0001" class="usa-link">1</a>). Of the 90 participants who completed the study, 28 were recruited through physician panels, and 62 were recruited through the PBCers Organisation. The 90 participants who completed the study were stratified into the NMP group (<em>N</em> = 40) and the MSP group (<em>N</em> = 50).</p>
<figure class="fig xbox font-sm" id="liv70276-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f9/12374225/ab213e3621db/LIV-45-0-g001.jpg" loading="lazy" id="jats-graphic-1" height="266" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/liv70276-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow diagram of recruitment process. NRS, numerical rating scale; OCA, obeticholic acid; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid. * Individuals answered all screening questions before being disqualified. Therefore, some individuals had multiple reasons for disqualification from this study.</p></figcaption></figure><p>Participants were mostly female, with a mean age of 56.7 years (SD: 12.1) in the NMP group and 52.1 years (SD: 12.2) in the MSP group (Table <a href="#liv70276-tbl-0001" class="usa-link">1</a>). The mean level of itch at baseline as measured by the Pruritus NRS was 1.3 for the NMP group and 6.2 for the MSP group. All participants in the study had health insurance coverage, with over half using private health insurance. The mean time to diagnosis from the initial presentation of disease‐related symptoms or first healthcare provider contact regarding these symptoms or other findings (e.g., laboratory abnormalities detected during routine screening) was 1.1 years (SD: 1.9) in the NMP group and 1.0 years (SD: 1.6) in the MSP group. PBC was most commonly initially suspected due to abnormal results found during routine blood work (60% in the NMP group; 64% in the MSP group). All patients had at least one comorbidity; the most common comorbidities were high blood pressure, anxiety, and Raynaud's syndrome. Seven (18%) and 10 (20%) participants had cirrhosis at the time of the study, with one (3%) and seven (14%) experiencing complications related to cirrhosis (variceal bleeding, ascites, or hepatic encephalopathy) in the NMP and MSP groups, respectively (Table <a href="#liv70276-tbl-0001" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="liv70276-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Patient characteristics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">NMP (<em>N</em> = 40)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">MSP (<em>N</em> = 50)</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="3" valign="top" rowspan="1">Recruitment avenue, <em>n</em> (%)</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Physician panel</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (25)</td>
<td align="center" valign="top" rowspan="1" colspan="1">18 (36)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PBCers advocacy group</td>
<td align="center" valign="top" rowspan="1" colspan="1">30 (75)</td>
<td align="center" valign="top" rowspan="1" colspan="1">32 (64)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Gender</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">34 (85)</td>
<td align="center" valign="top" rowspan="1" colspan="1">40 (80)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (13)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non‐binary, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Ethnicity<a href="#liv70276-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">31 (78)</td>
<td align="center" valign="top" rowspan="1" colspan="1">36 (72)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic or Latino, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (16)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black or African American, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Native American or American Indian, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asian/Pacific Islander, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (15)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Age (years)</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">56.7 (12.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">52.1 (12.2)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td>
<td align="center" valign="top" rowspan="1" colspan="1">56.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">52.0</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Age at PBC diagnosis (years)</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">48.9 (11.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">44.5 (9.5)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td>
<td align="center" valign="top" rowspan="1" colspan="1">48.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">45.5</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Time to PBC diagnosis (years)</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.1 (1.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0 (1.6)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Years since PBC diagnosis</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7.7 (8.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7.6 (6.8)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.5</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Mean level of itch at baseline</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Itch score (SD)<a href="#liv70276-note-0005" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6.2 (1.7)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Health insurance coverage<a href="#liv70276-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Overall, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">40 (100)</td>
<td align="center" valign="top" rowspan="1" colspan="1">50 (100)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Private Insurance, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">21 (53)</td>
<td align="center" valign="top" rowspan="1" colspan="1">26 (52)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medicare, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (23)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (16)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medicaid/CHIP, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (13)</td>
<td align="center" valign="top" rowspan="1" colspan="1">17 (34)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">VA/DoD/TRICARE, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (15)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Comorbidities<a href="#liv70276-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High blood pressure, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (25)</td>
<td align="center" valign="top" rowspan="1" colspan="1">11 (22)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Raynaud's syndrome, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (23)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Anxiety, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (23)</td>
<td align="center" valign="top" rowspan="1" colspan="1">11 (22)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabetes, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (13)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sjögren's syndrome, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (10)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High cholesterol, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asthma, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Rheumatoid arthritis, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bipolar/psychotic disorders, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fibromyalgia/chronic fatigue syndrome, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other<a href="#liv70276-note-0006" class="usa-link">
<sup>c</sup>
</a>, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (23)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Cirrhosis status</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cirrhosis of the liver, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (18)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Complications due to cirrhosis, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (14)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Employment status<a href="#liv70276-note-0007" class="usa-link">
<sup>d</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Employed, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">21 (53)</td>
<td align="center" valign="top" rowspan="1" colspan="1">21 (42)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unemployed, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">19 (47)</td>
<td align="center" valign="top" rowspan="1" colspan="1">29 (58)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70276-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70276-note-0003"><p>Abbreviations: CHIP, Children's Health Insurance Program; DoD, Department of Defense; MSP, moderate/severe; NMP, no/mild pruritus; PBC, primary biliary cholangitis; SD, standard deviation; VA, Veterans Affairs.</p></div>
<div class="fn" id="liv70276-note-0004">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Participants were asked to select all applicable responses, allowing for multiple selections. Therefore, the responses were not mutually exclusive.</p>
</div>
<div class="fn" id="liv70276-note-0005">
<sup>
<sup>b</sup>
</sup><p class="display-inline">As measured by Pruritus Numerical Rating Scale (NRS); No/Mild Pruritus = Pruritus NRS score of 0–3 and Moderate/Severe Pruritus = Pruritus NRS score of 4–10.</p>
</div>
<div class="fn" id="liv70276-note-0006">
<sup>
<sup>c</sup>
</sup><p class="display-inline">In the NMP group, other comorbidities were the following: lupus, limited scleroderma, cirrhosis, Hashimoto's thyroiditis, Sjogren's syndrome, irritable bowel syndrome (IBS), and thyroid. In the MSP group, other comorbidities were the following: achalasia, atrial fibrillation, chronic obstructive pulmonary disease (COPD), Crohn's disease, Hashimoto's thyroiditis, and hypothyroidism.</p>
</div>
<div class="fn" id="liv70276-note-0007">
<sup>
<sup>d</sup>
</sup><p class="display-inline">WPAI scores (except for the activity impairment score) were calculated only for participants who indicated they were currently employed and provided complete and interpretable WPAI data (NMP: <em>n</em> = 21; MSP: <em>n</em> = 17). WPAI scores were excluded for four participants in the MSP group due to responses that were nonsensical and rendered the data uninterpretable.</p>
</div>
</div></section></section><section id="liv70276-sec-0016"><h3 class="pmc_sec_title">3.2. Patient‐Reported Outcomes</h3>
<p>The unadjusted mean scores for the PBC‐40, CLDQ‐PBC, FACIT‐Fatigue, 5‐D Itch, EQ‐5D‐5L, and WPAI by NMP and MSP groups are presented in Table <a href="#liv70276-tbl-0002" class="usa-link">2</a>. Directionally, patients in the MSP group had worse scores across each of the domains of all of the PRO measures included in this study compared to the NMP group.</p>
<p>Table <a href="#liv70276-tbl-0003" class="usa-link">3</a> presents the regression results for each of the PRO measures, controlling for age, gender, ethnicity, and treatment. Figure <a href="#liv70276-supitem-0001" class="usa-link">S1</a> also presents the results of the regression analysis, highlighting which group experienced worse outcomes for each PRO measure/domain, along with interpretations of these results.</p>
<section class="tw xbox font-sm" id="liv70276-tbl-0003"><h4 class="obj_head">TABLE 3.</h4>
<div class="caption p"><p>Regression results assessing differences in PRO scores by NMP and MSP groups.<a href="#liv70276-note-0012" class="usa-link">
<sup>a</sup>
</a>
</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Outcome</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Coefficient (MSP vs NMP Group)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">
<em>p</em>
</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="4" valign="top" rowspan="1">5‐D itch score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.87</td>
<td align="center" valign="top" rowspan="1" colspan="1">(3.56, 6.18)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr><td align="left" colspan="4" valign="top" rowspan="1">EQ‐5D‐5L score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">EQ‐5D Index</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.14</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−0.24, −0.04)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.005</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">EQ VAS</td>
<td align="center" valign="top" rowspan="1" colspan="1">−3.58</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−11.01, 3.85)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.348</td>
</tr>
<tr><td align="left" colspan="4" valign="top" rowspan="1">PBC‐40 domain scores</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Symptoms</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.26</td>
<td align="center" valign="top" rowspan="1" colspan="1">(0.55, 3.97)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.011</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Itch</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.18</td>
<td align="center" valign="top" rowspan="1" colspan="1">(2.91, 5.45)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
<td align="center" valign="top" rowspan="1" colspan="1">7.24</td>
<td align="center" valign="top" rowspan="1" colspan="1">(3.63, 10.85)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Cognitive</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.53</td>
<td align="center" valign="top" rowspan="1" colspan="1">(1.43, 5.63)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Emotional</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.72</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−0.46, 1.90)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.239</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Social</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.18</td>
<td align="center" valign="top" rowspan="1" colspan="1">(0.67, 7.69)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.022</td>
</tr>
<tr><td align="left" colspan="4" valign="top" rowspan="1">FACIT‐Fatigue score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total</td>
<td align="center" valign="top" rowspan="1" colspan="1">−8.26</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−12.85, −3.67)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr><td align="left" colspan="4" valign="top" rowspan="1">CLDQ‐PBC score</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.87</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.38, −0.36)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr><td align="left" colspan="4" valign="top" rowspan="1">CLDQ‐PBC domain scores</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Diet</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.75</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.27, −0.23)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.006</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Emotional</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.66</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.22, −0.10)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.024</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.92</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.42, −0.43)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Itch</td>
<td align="center" valign="top" rowspan="1" colspan="1">−1.73</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−2.32, −1.14)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sleep</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.82</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.50, −0.13)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.022</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Symptoms</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.87</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.31, −0.43)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Worry</td>
<td align="center" valign="top" rowspan="1" colspan="1">−0.35</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−1.02, 0.32)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.306</td>
</tr>
<tr><td align="left" colspan="4" valign="top" rowspan="1">WPAI scores</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% activity impairment due to PBC</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.20</td>
<td align="center" valign="top" rowspan="1" colspan="1">(0.08, 0.32)</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% work time missed due to PBC (absenteeism)<a href="#liv70276-note-0013" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.04</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−0.06, 0.14)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.349</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% impairment while working due to PBC (presenteeism)<a href="#liv70276-note-0013" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.17</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−0.03, 0.37)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.236</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">% overall work impairment due to PBC<a href="#liv70276-note-0013" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.13</td>
<td align="center" valign="top" rowspan="1" colspan="1">(−0.07, 0.33)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.204</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70276-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70276-note-0010"><p>
<em>Note:</em> As an example, a regression coefficient of 4.87 indicates that being in the MSP group is associated with an increase in the 5‐D Itch total score by 4.87 points (scores range from 5–25, with higher scores indicating more severe itch and negative impact).</p></div>
<div class="fn" id="liv70276-note-0011"><p>Abbreviations: 5‐D Itch Scale, 5‐D Pruritus Scale; CI, confidence interval; CLDQ, Chronic Liver Disease Questionnaire; EQ‐5D‐5L, EuroQol 5‐Dimension 5‐Level; FACIT‐Fatigue, Functional Assessment of Chronic Illness Therapy – Fatigue Scale; MSP, moderate/severe pruritus; NMP, no/mild pruritus; PBC, primary biliary cholangitis; SD, standard deviation; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment Questionnaire.</p></div>
<div class="fn" id="liv70276-note-0012">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Adjusting for age, gender, ethnicity, obeticholic acid, and ursodeoxycholic acid treatment.</p>
</div>
<div class="fn" id="liv70276-note-0013">
<sup>
<sup>b</sup>
</sup><p class="display-inline">WPAI scores (except for the activity impairment score) were calculated only for participants who indicated they were currently employed and provided complete and interpretable WPAI data (NMP: <em>n</em> = 21; MSP: <em>n</em> = 17). WPAI scores were excluded for four participants in the MSP group due to responses that were nonsensical and rendered the data uninterpretable.</p>
</div>
</div></section><p>Compared with the NMP group, the MSP group had significantly worse 5‐D Itch total scores (<em>p</em> &lt; 0.001) and EQ‐5D Index scores (<em>p</em> = 0.005). Additionally, the MSP group had significantly worse PBC‐40 mean scores in the Symptom, Itch, Fatigue, Cognitive, and Social domains (all <em>p</em> &lt; 0.05); but not in the Emotional domain (<em>p</em> = 0.239). The MSP group also had worse total FACIT‐Fatigue and CLDQ‐PBC scores (both <em>p</em> &lt; 0.001) compared to the NMP group. Additionally, the MSP group had significantly lower (worse) CLDQ‐PBC scores across the Diet, Emotional, Fatigue, Itch, Sleep, and Symptoms domains (all <em>p</em> &lt; 0.05).</p>
<p>Participants in the MSP group reported higher rates of sleep disturbance and daytime sleepiness than those in the NMP group. In the 5‐D Itch assessment, 45% of NMP participants indicated that itching “never affects sleep,” and another 45% indicated it “occasionally delays falling asleep,” compared to only 6% and 34% of MSP participants, respectively. More severe effects (“delays falling asleep and occasionally/frequently wakes me up at night”) were reported by 24% and 14% of MSP participants, versus 8% and 0% in the NMP group.</p>
<p>Data from the CLDQ‐PBC similarly highlighted the greater sleep‐related burden in the MSP group. Feeling sleepy during the day “all of the time” or “most of the time” was reported by 38% of MSP participants, versus 21% in the NMP group. Difficulty sleeping at night was reported at the same frequency (i.e., either “all of the time” or “most of the time”) by 36% of MSP participants, compared to 11% of NMP participants. Notably, 22% of MSP participants reported being disturbed by itching in their sleep “all of the time” or “most of the time,” compared to just 3% of NMP participants. These findings underscore a higher prevalence of pruritus‐associated sleep disruption in the MSP group.</p>
<p>The MSP group also reported significantly greater activity impairment due to PBC (57% in the MSP group vs 36% in the NMP group; <em>p</em> &lt; 0.001). Additionally, the percentage of patients who were employed was lower in the MSP group (42%) compared to the NMP group (53%). Among employed individuals, the MSP group demonstrated higher rates of work absenteeism, decreased productivity while at work, and greater overall work‐related impairment from PBC compared to the NMP group. Differences in the WPAI scores related to work productivity were not statistically significant (Table <a href="#liv70276-tbl-0003" class="usa-link">3</a>).</p>
<p>Of the 21 patients working for pay in the NMP group and 17 in the MSP group, 6% and 10% of work time, respectively, was missed in the past week due to their health problem (absenteeism). Among the 19 (48%) patients in the NMP group and 29 (58%) in the MSP group who were not working for pay, a greater proportion of those in the NMP group were aged ≥ 65 (8 of 19, 42%) compared with the MSP group (5 of 29, 17%). This suggests that if age‐related retirement contributed to unemployment, its impact was likely more pronounced in the NMP group. Among these same patients not working for pay, the perceived impact of PBC on the ability to perform daily activities (other than paid work), rated on a scale from 0 (PBC had no effect on my daily activities) to 10 (PBC completely prevented me from doing my daily activities), averaged 4.1 in the NMP group and 5.7 in the MSP group. Additionally, 32% of work in the NMP group and 47% in the MSP group was impaired due to their health problem (presenteeism).</p></section><section id="liv70276-sec-0017"><h3 class="pmc_sec_title">3.3. Patient Treatment Experience</h3>
<p>The breakdown of PBC treatments for the NMP and MSP groups is presented in Table <a href="#liv70276-tbl-0004" class="usa-link">4a</a>. In the NMP group, most patients were treated with UDCA (88%) and/or OCA (18%). Similarly, in the MSP group, most patients were treated with UDCA (74%) and/or OCA (30%). A small percentage of patients were receiving treatment for their pruritus at the time of the study. Four patients (10%) from the NMP group were receiving at least one of the following treatments for pruritus: antihistamines, antibiotics, bile acid sequestrants, gabapentin, or opiate antagonists, compared to eleven patients (22%) from the MSP group. Among the 50 MSP participants, each of the following pruritus treatments was used by at least one participant: antihistamines, antibiotics, bile acid sequestrants, gabapentin, and opiate antagonists. In contrast, the use of antihistamines, bile acid sequestrants, and gabapentin was not observed in the NMP group.</p>
<section class="tw xbox font-sm" id="liv70276-tbl-0004"><h4 class="obj_head">TABLE 4a.</h4>
<div class="caption p"><p>Current PBC treatment.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">NMP (<em>N</em> = 40)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">MSP (<em>N</em> = 50)</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="3" valign="top" rowspan="1">Current PBC treatment<a href="#liv70276-note-0015" class="usa-link">
<sup>a</sup>
</a>
</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ursodeoxycholic acid, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">35 (88)</td>
<td align="center" valign="top" rowspan="1" colspan="1">37 (74)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Obeticholic acid, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (18)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (30)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fibrates, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
<tr><td align="left" colspan="3" valign="top" rowspan="1">Current pruritus treatments<a href="#liv70276-note-0015" class="usa-link">
<sup>a</sup>
</a>
</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Antihistamines, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (16)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Antibiotics<a href="#liv70276-note-0016" class="usa-link">
<sup>b</sup>
</a>, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bile acid sequestrants, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gabapentin, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Opiate antagonists, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70276-tbl-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70276-note-0014"><p>Abbreviations: MSP, moderate/severe pruritus; NMP, no/mild pruritus; PBC, primary biliary cholangitis.</p></div>
<div class="fn" id="liv70276-note-0015">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Participants were asked to provide reasons for discontinuing their treatments. Multiple selections were allowed, so the responses were not mutually exclusive.</p>
</div>
<div class="fn" id="liv70276-note-0016">
<sup>
<sup>b</sup>
</sup><p class="display-inline">Rifampicin (rifampin) or vancomycin was the antibiotic included.</p>
</div>
</div></section><p>Patients discontinued UDCA and OCA for different reasons, with ineffectiveness being the most common (reported in 0% and 50% of UDCA and OCA discontinuations in the NMP group, and in 75% and 100% in the MSP group, respectively) (Table <a href="#liv70276-tbl-0005" class="usa-link">4b</a>). Other treatments, such as bile acid sequestrants, antihistamines, gabapentin, and fibrates, were also discontinued for various reasons, most commonly due to ineffectiveness or following doctor recommendations. Approximately two‐thirds of MSP group patients who discontinued bile acid sequestrants reported ineffectiveness as a reason for discontinuation (<em>n</em> = 8; 67%) (Table <a href="#liv70276-tbl-0005" class="usa-link">4b</a>). Table <a href="#liv70276-tbl-0005" class="usa-link">4b</a> provides details regarding the reasons for discontinuing PBC treatments over the past three years for all treatments.</p>
<section class="tw xbox font-sm" id="liv70276-tbl-0005"><h4 class="obj_head">TABLE 4b.</h4>
<div class="caption p"><p>Reasons for discontinuing PBC treatments in the past 3 years.<a href="#liv70276-note-0019" class="usa-link">
<sup>a</sup>
</a>
</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">NMP (<em>N</em> = 40), <em>n</em> (%)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">MSP (<em>N</em> = 50), <em>n</em> (%)</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ursodeoxycholic acid</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ineffective</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (75)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Side effects</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (25)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Preferred alternative therapy</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (25)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Symptoms improved</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (25)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Obeticholic acid</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ineffective</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (100)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Side effects</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Doctor recommendation</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fibrates</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ineffective</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (100)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Side effects</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Doctor recommendation</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Antihistamines</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ineffective</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (33)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (67)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Side effects</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (33)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Symptoms improved</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (33)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (33)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Antibiotics</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Side effects</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (100)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Doctor recommendation</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (100)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Bile acid sequestrants</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (24)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ineffective</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (100)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (67)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Side effects</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (8)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cost</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (17)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Doctor recommendation</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (42)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Gabapentin</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ineffective</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (80)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Doctor recommendation</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (100)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (20)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sertraline</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Symptoms improved</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (100)</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70276-tbl-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70276-note-0017"><p>
<em>Note:</em> All reasons for discontinuation percentages are based on the number of patients discontinuing each specific drug.</p></div>
<div class="fn" id="liv70276-note-0018"><p>Abbreviations: MSP, moderate/severe pruritus; NMP, no/mild pruritus; PBC, primary biliary cholangitis.</p></div>
<div class="fn" id="liv70276-note-0019">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Participants were asked to provide reasons for discontinuing their treatments. Multiple selections were allowed, so the responses were not mutually exclusive.</p>
</div>
</div></section></section><section id="liv70276-sec-0018"><h3 class="pmc_sec_title">3.4. Patient Voice Findings on Impact of PBC and Pruritus</h3>
<p>Patient voice data highlighted the debilitating impact of PBC‐related itching. PBC‐related pruritus was described as unrelenting, deep, diffuse, mobile, and formication‐like (sensation of bugs crawling under one's skin), distinct from dermatological itches, with terms such as “sharpness,” “abrasion,” and “heat” used to describe it. Patients referred to their PBC as an “invisible illness” marked by fatigue, brain fog, and functional limitations. Many expressed significant anxiety and fear due to the uncertain prognosis. The detrimental effect of itch on job performance was highlighted, with several patients noting that lack of sleep and the itch itself make focusing on work difficult. The burdens of pruritus negatively impact emotional well‐being, especially due to its constant, unrelenting nature. See Table <a href="#liv70276-tbl-0006" class="usa-link">5</a> for exemplary quotes describing the impact of PBC and pruritus from the patients' perspective.</p>
<section class="tw xbox font-sm" id="liv70276-tbl-0006"><h4 class="obj_head">TABLE 5.</h4>
<div class="caption p"><p>Exemplary quotes from patients collected using the voice response system.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Themes</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Exemplary quotes<a href="#liv70276-note-0020" class="usa-link">
<sup>a</sup>
</a>
</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2" valign="top" colspan="1">Description of pruritus: patients describe pruritus presents as unrelenting, deep, diffuse, mobile, and formication‐like itch, which is unlike dermatologically based itches</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“It's an itch that's so far down in your system, almost like to your bones in a way.”</em>
</td>
</tr>
<tr><td align="center" valign="top" rowspan="1" colspan="1">
<em>“The way that I experience it is mainly it feels like a bunch of very tiny bugs are crawling just underneath the first layer of your skin. And you can't quite move them, you can't get them away, and they are just constantly crawling in every direction.”</em>
</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of emotional effects related to PBC and the uncertain prognosis: patients describe feelings of anxiety and stress as a result of an uncertain future</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“So, that thing hanging over your head of, ‘Do I have an expiration date over my head?’ And no one can tell you for sure yes or no, which is sometimes part of life, but you're a lot more aware of it on a day‐to‐day basis… it can be really overwhelming, especially when you think of your kids, especially when you think of your partner.”</em>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of fatigue: patients describe fatigue as an overwhelming and pervasive symptom of PBC that severely limits their daily activities and overall energy</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“PBC in my daily life is mostly something hanging over me, the biggest thing being the fatigue. It lays over you like a blanket all the time. You have the itch as well, but the biggest day to day… is that fatigue of never going to be having enough energy, never going to have as much energy as you used to have.”</em>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of cognitive effects: patients describe brain fog, memory loss, and confusion lead to a functional deficit, preventing patients from thinking clearly and recalling information as they would like</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“I feel that PBC is a problem that on occasion can affect your mental stability. It can make you have a foggy brain. It can also make you forget things. There can be some days where you're so tired that you don't feel like you want to get out of bed. There are also days when you're working that it's difficult to maybe complete your assignment without taking a break.”</em>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of the impact on sleep: patients explain that they believe they would be able to sleep through the night without the itch</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“I might actually be able to sleep most nights, unlike what I'm doing now… It's nearly impossible to get comfortable when you're busy scratching all the time.”</em>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of impacts on work: patients explain how itch impacts their work by distracting them and making it ‘hard to focus’ or accomplish tasks</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“It's hard for me to sleep, and then I have a hard time at work, hard time focusing. And then, on top of that, I'm itching while I'm at work, which makes it very hard to focus, it's very distracting, and very hard to get anything done. So, I'm less productive.”</em>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of emotional effects related to pruritus: patients describe feelings of frustration as a result of persistent itching</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“I know it's been very frustrating at times when I'm just trying to sit down and watch a movie… I'm itching so hard I can't focus on the movie, and I'm like, I can't even relax. So, emotionally that's really hard, when you can't relax at certain points, because this itching is just constant…”</em>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Description of the impact of treatments on patients' itching: patients report trying numerous topical and oral treatments available over the counter and by prescription to treat their itching</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>“I tried everything that you can buy in the supermarket that's topical. I even saved some [cream] that I had for surgery procedure and experimented with my own concoctions, and I know that's not good, but that didn't work either. So, I don't know.”</em>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70276-tbl-0006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="liv70276-note-0020">
<sup>
<sup>a</sup>
</sup><p class="display-inline">All patient quotes were from participants in the MSP group.</p>
</div></div></section></section><section id="liv70276-sec-0019"><h3 class="pmc_sec_title">3.5. Patient Voice Findings – Perceptions of Pruritus Treatment</h3>
<p>Patients reported trying various over‐the‐counter and prescription topical and oral treatments to relieve their itching, but most reported receiving little to no relief from PBC‐related pruritus. For those who experienced relief, the effects were described as brief or minimal. Patients expressed frustration by the lack of effective treatments, with some options failing to address the itch and causing side effects like drowsiness. They reported a desire for lasting relief that also prevents liver damage, describing such improvement as “fantastic,” “a miracle,” allowing them to “be like a normal person,” and “actually sleep.” See Table <a href="#liv70276-tbl-0006" class="usa-link">5</a> for a quotation from a patient about their experience with pruritus treatments.</p></section></section><section id="liv70276-sec-0020"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>This study demonstrates that patients with moderate‐to‐severe pruritus experience a significantly greater negative impact on HRQoL than those without pruritus or with mild pruritus, across a broad range of domains, including those related to itch, fatigue, and social and cognitive function. The MSP group had significantly lower health utility values and more impaired activity compared to the NMP group. The findings from validated PRO measures are further supported by patient voice data, which emphasise how the persistent nature of pruritus substantially impairs productivity, social functioning, and emotional well‐being. Additionally, WPAI Questionnaire data revealed differences in non‐work activities and employment rates between the MSP and NMP groups.</p>
<p>The WPAI questionnaire has had limited use in studies assessing work productivity among patients with PBC [<a href="#liv70276-bib-0035" class="usa-link" aria-describedby="liv70276-bib-0035">35</a>]. Our WPAI analysis showed significantly greater non‐work activity impairment in patients with moderate/severe pruritus compared to those with no/mild pruritus (<em>p</em> &lt; 0.001). Employment rates were also lower in the MSP group (42%) compared to the NMP group (53%). Among employed individuals, the MSP group reported more missed work, higher work‐related impairment, and greater overall work impairment due to PBC. These differences did not reach statistical significance, potentially because less than half of the participants (47%) were employed. The impact on patients' ability to work (absenteeism) and their productivity at work (presenteeism) has implications for the financial burden patients may face because of their PBC‐related pruritus. One study analysing published literature found that the costs of presenteeism could be up to three times those of absenteeism in the US [<a href="#liv70276-bib-0036" class="usa-link" aria-describedby="liv70276-bib-0036">36</a>]. Further research is required to quantify the indirect costs associated with PBC‐related absenteeism and presenteeism.</p>
<p>Our findings are consistent with earlier studies on the impact of PBC on patients' HRQoL [<a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>], confirming that those with more severe pruritus have worse scores across multiple domains, including symptoms, physical health, cognitive function, and social and emotional well‐being. The present study builds upon previous research by comprehensively assessing various aspects of pruritus in PBC, with a particular focus on its impact on HRQoL in PBC patients. To evaluate HRQoL, multiple validated instruments were administered, including the PBC‐40, CLDQ‐PBC, 5‐D Itch, EQ‐5D‐5L, and FACIT‐Fatigue. As previously noted, the WPAI Questionnaire was used to assess the impact of pruritus on work productivity and activity impairment, an area not extensively explored in prior studies on this population. Notably, the PBC‐40 and CLDQ‐PBC, two well‐established tools specifically designed for PBC patients, were included, both of which have demonstrated reliability and validity in this population [<a href="#liv70276-bib-0010" class="usa-link" aria-describedby="liv70276-bib-0010">10</a>, <a href="#liv70276-bib-0014" class="usa-link" aria-describedby="liv70276-bib-0014">14</a>, <a href="#liv70276-bib-0015" class="usa-link" aria-describedby="liv70276-bib-0015">15</a>, <a href="#liv70276-bib-0016" class="usa-link" aria-describedby="liv70276-bib-0016">16</a>].</p>
<p>Although no significant differences were observed between the NMP and MSP groups in the Emotional domain of the PBC‐40 (<em>p</em> = 0.239), several factors may have contributed to this finding. One possibility is that patients experience emotional adaptation over time, which may attenuate measurable differences between groups, even when disparities in other symptom domains are present [<a href="#liv70276-bib-0037" class="usa-link" aria-describedby="liv70276-bib-0037">37</a>]. Additionally, because the PBC‐40 Emotional domain assesses the emotional impact of PBC as a whole, the overall emotional burden of the disease, given its morbidity and mortality, may influence patients in addition to the impact of changing symptoms.</p>
<p>PBC is also associated with sleep disturbances [<a href="#liv70276-bib-0038" class="usa-link" aria-describedby="liv70276-bib-0038">38</a>]. Findings from our study were consistent with prior literature, with participants in the MSP group reporting higher rates of (1) sleep disruption due to itching, as measured by the 5‐D Itch, and (2) daytime sleepiness, difficulty sleeping at night, and being disturbed by itching during sleep, as measured by the CLDQ‐PBC, compared to those in the NMP group.</p>
<p>Despite the substantial impact of pruritus on patients' quality of life, only 22% of those in the MSP group were taking treatment for pruritus, with limited efficacy being the most common reason for discontinuation (Table <a href="#liv70276-tbl-0005" class="usa-link">4b</a>). Low awareness of pruritus burden and available treatment options may also be contributors to the low proportion of patients treated for pruritus [<a href="#liv70276-bib-0013" class="usa-link" aria-describedby="liv70276-bib-0013">13</a>]. Notably, OCA use was higher in the MSP group (30% vs 18% in the NMP group); thus, the possibility of OCA‐induced pruritus may be slightly higher in this group, as OCA is known to exacerbate pruritus in some patients. A systematic literature review recently published identified a lack of reliable evidence regarding the effectiveness, quality of life impact, and safety of treatments for cholestatic pruritus. Consequently, clinicians are often forced to rely on clinical experience rather than evidence‐based medicine when selecting treatment approaches [<a href="#liv70276-bib-0013" class="usa-link" aria-describedby="liv70276-bib-0013">13</a>]. Consistent with this, our study found that antihistamines were the most commonly used medication among patients receiving pruritus treatment, despite antihistamines not being recommended as first‐line therapy in current European Association for the Study of the Liver and American Association for the Study of Liver Diseases guidelines [<a href="#liv70276-bib-0005" class="usa-link" aria-describedby="liv70276-bib-0005">5</a>, <a href="#liv70276-bib-0008" class="usa-link" aria-describedby="liv70276-bib-0008">8</a>, <a href="#liv70276-bib-0039" class="usa-link" aria-describedby="liv70276-bib-0039">39</a>].</p>
<p>Together, these findings highlight the need for (1) better education about PBC, its associated symptoms, and available treatments, (2) improved strategies for guideline implementation, and (3) more efficacious drugs specifically for the management of pruritus in PBC.</p>
<p>Patients reported intense pruritus and stressed that effective treatment could improve well‐being and reduce anxiety, fatigue, and isolation. Patient voice data underscores the value of a treatment that alleviates pruritus, with one participant with moderate‐to‐severe pruritus remarking that such a treatment would be “<em>a miracle, [allowing them] to actually go out again and do things that [they] enjoy</em>.”</p>
<p>The precise cause of pruritus in PBC remains elusive [<a href="#liv70276-bib-0040" class="usa-link" aria-describedby="liv70276-bib-0040">40</a>]. Disturbances in bile acid homeostasis are believed to contribute to cholestatic itch, and treatments that reduce bile acid levels may have the potential to alleviate pruritus [<a href="#liv70276-bib-0040" class="usa-link" aria-describedby="liv70276-bib-0040">40</a>]. In a clinical trial of seladelpar in patients with PBC, reductions in interleukin‐31 and bile acids were closely correlated with improvements in pruritus, suggesting a potential mechanism for the observed antipruritic effects [<a href="#liv70276-bib-0041" class="usa-link" aria-describedby="liv70276-bib-0041">41</a>].</p>
<p>Strengths of this study include the inclusion of an ethnically diverse patient population that is comparable to the general PBC population in terms of patient characteristics. The mixed‐methods approach, which combines validated PRO instruments to assess quality of life with a voice response system to capture the patient's perspective, enhances the validity of our research and offers a more holistic understanding of the patients' experiences. Moreover, the comprehensiveness of the PROs included along with the consistency of the results adds robustness and reliability to these findings. Treatment experiences were captured and expanded on previous research by collecting data on the reasons patients discontinue PBC treatments. Finally, this study encompasses patients with PBC who exhibit a wide spectrum of pruritus experiences, ranging from no pruritus to severe pruritus.</p>
<p>While the generalizability of the findings to the broader PBC population may be limited by the small sample size, it is important to note that the target sample size was determined based on a power calculation focused on differences in HRQoL. The low proportion of employed participants likely resulted in insufficient statistical power to detect significant differences between groups on work productivity variables. For example, the limited number of employed participants may specifically affect the applicability of the results to the broader working population. Some participants were recruited via advocacy groups, and although they may have had a confirmed diagnosis of PBC, this information could not be verified; therefore, the possibility of misclassification bias cannot be ruled out. Other limitations include potential recall bias, a common issue in patient surveys, which may affect the accuracy of self‐reported data. Data were not explicitly collected regarding the presence of other comorbid conditions potentially associated with pruritus (e.g., eczema, dermatitis); thus, the possibility that these conditions may have influenced the assessment of PBC‐specific pruritus cannot be excluded. Regarding treatments evaluated, the study did not examine specific medication doses, titration schedules, or combinations of therapies. In our study, all participants were insured; uninsured individuals may have different treatment experiences due to potential differences in access to care. Lastly, the mechanism underlying PBC‐related pruritus is not fully understood, so attributing pruritus specifically to PBC cannot be definitively confirmed.</p>
<p>This study expands on prior analyses and provides further evidence that people with PBC, representing diverse racial and ethnic backgrounds, who have moderate‐to‐severe pruritus experience reduced activity and a greater HRQoL burden compared to those with mild/no pruritus. Despite this, individuals with PBC who experience this symptom report infrequent use of treatments targeting pruritus (itching), with minimal or no relief from their itch. There is a clear unmet need for safe and effective treatments that address pruritus and improve associated HRQoL outcomes. As emerging therapies are developed for patients with PBC to address unmet medical needs, future research should focus on the patient experience, particularly pruritus, given its far‐reaching negative impacts on HRQoL.</p></section><section id="liv70276-sec-0021"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>C.F.M.P., J.I., Z.M.Y., R.Z., D.I., and B.P. contributed to the study concept and design, questionnaire development, and interpretation of the results. R.Z., D.I., and B.P. were responsible for study execution, ethics approval, data collection, and statistical analysis. C.L., Z.M.Y., M.J.M., A.E.K., and J.P. contributed to the discussion and interpretation of findings. All authors critically revised the manuscript for important intellectual content, contributed significantly to finalising the manuscript, and approved the final version for publication.</p></section><section id="liv70276-sec-0024"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>C.L. has served as a consultant to Gilead Sciences, Intercept, Ipsen, Mirum, CymaBay, GSK, Calliditas, and Kowa. She has received research grants/contracts from Gilead Sciences, Intercept, Mirum, Zydus, CymaBay, GSK, Escient, Calliditas, Ipsen, and Kowa. She has also participated in a Data Safety Monitoring Board for COUR Pharmaceuticals. Z.M.Y. has received research funding and/or served as a consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, Novo Nordisk, Ipsen, AstraZeneca, Siemens, Madrigal, Merck, and Abbott. J.I. and C.F.M.P. are employees of Gilead who, in the course of their employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Gilead Sciences. R.Z., B.P., and D.I. are employees of Stratevi, a research consulting firm that received funding from Gilead Sciences, previously CymaBay, to conduct this study. M.J.M. has received grants or contracts from CymaBay, Genfit, Gilead Sciences, GSK, Ipsen, and Mirum Pharma. She has received consulting fees from CymaBay, GSK, Intra‐Sana, Ipsen, Ironwood, Mallinckrodt, and Mirum Pharma. She has also received support for attending meetings and/or travel from CymaBay, GSK, Ipsen, and Mallinckrodt. A.E.K. has received grants or contracts from Gilead and Intercept. He has received consulting fees from AbbVie, Advanz Pharma, Alentis, Alfasigma, AstraZeneca, Avior Bio, Bayer, BMS, CymaBay, Escient, Falk, Gilead, GSK, Guidepoint, Intercept, Ipsen, Mirum Pharma, Merck Sharp &amp; Dohme, Novo Nordisk, Roche, and Takeda. He has also received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AbbVie, Advanz Pharma, AOP Orphan, Bayer, BMS, CymaBay, Falk, Gilead, GSK, Intercept, Ipsen, Johnson &amp; Johnson, Medscape, Mirum Pharma, Merck Sharp &amp; Dohme, NewBridge, Novartis, Roche, Vertex, and Viofor. He has also received support for attending meetings and/or travel from Gilead and participated on a data safety monitoring board with AbbVie, Advanz Pharma, Alentis, Alfasigma, AstraZeneca, Avior Bio, Bayer, BMS, CymaBay, Escient, Falk, Gilead, GSK, Guidepoint, Intercept, Ipsen, Mirum, Merck Sharp &amp; Dohme, Novo Nordisk, Roche, and Takeda. A.E.K. has had a leadership or fiduciary role (paid or unpaid) with PBC Foundation, Swiss Association for the Study of the Liver, Swiss Gastroenterology Society, Swiss Hepa, and Swiss Transplant Society.</p></section><section id="sec21"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="liv70276-supitem-0001"><div class="caption p"><p>
<strong>Figure S1:</strong> PRO outcomes by group based on regression analysis: no/mild pruritus (NMP) vs moderate/severe pruritus (MSP).</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374225/bin/LIV-45-0-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">LIV-45-0-s001.docx</a><sup> (5.8MB, docx) </sup>
</div></div></section></section><section id="liv70276-sec-0025" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We gratefully acknowledge the contributions of Roy Arguello, who conducted the data analysis, and Chris Bly, who assisted in the development of the content for this manuscript. We are grateful for the support and contributions of the PBCers Organisation, an online and in‐person support group for individuals with PBC, their care partners, and healthcare team members in assisting with patient recruitment.</p></section><section id="notes1"><p>

Levy C., Younossi Z. M., Mayo M. J., et al., “Assessment of PBC Pruritus From the ITCH‐E Study: Quality of Life, Productivity, and Treatment Experiences,” Liver International
45, no. 9 (2025): e70276, 10.1111/liv.70276.
</p>
<section id="liv70276-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="liv70276-note-0001"><p>
<strong>Funding:</strong> This study was funded by Gilead Sciences Inc.</p></div>
<div class="fn p" id="liv70276-note-0002"><p>Jonathan Ieyoub was affiliated with CymaBay Therapeutics at the time the study was conducted.</p></div>
<div class="fn p" id="liv70276-note-0101"><p>
<strong>Handling Editor:</strong> Dr. Alessio Aghemo</p></div>
</div></section></section><section id="liv70276-sec-0023"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></section><section id="liv70276-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="liv70276-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="liv70276-bib-0001">
<span class="label">1.</span><cite>
Gulamhusein A. F. and Hirschfield G. M., “Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities,” Nature Reviews Gastroenterology &amp; Hepatology
17, no. 2 (2020): 93–110, 10.1038/s41575-019-0226-7.
</cite> [<a href="https://doi.org/10.1038/s41575-019-0226-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31819247/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Gastroenterology%20&amp;%20Hepatology&amp;title=Primary%20Biliary%20Cholangitis:%20Pathogenesis%20and%20Therapeutic%20Opportunities&amp;author=A.%20F.%20Gulamhusein&amp;author=G.%20M.%20Hirschfield&amp;volume=17&amp;issue=2&amp;publication_year=2020&amp;pages=93-110&amp;pmid=31819247&amp;doi=10.1038/s41575-019-0226-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0002">
<span class="label">2.</span><cite>
Lleo A., Wang G. Q., Gershwin M. E., and Hirschfield G. M., “Primary Biliary Cholangitis,” Lancet
396, no. 10266 (2020): 1915–1926, 10.1016/s0140-6736(20)31607-x.
</cite> [<a href="https://doi.org/10.1016/s0140-6736(20)31607-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33308474/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Primary%20Biliary%20Cholangitis&amp;author=A.%20Lleo&amp;author=G.%20Q.%20Wang&amp;author=M.%20E.%20Gershwin&amp;author=G.%20M.%20Hirschfield&amp;volume=396&amp;issue=10266&amp;publication_year=2020&amp;pages=1915-1926&amp;pmid=33308474&amp;doi=10.1016/s0140-6736(20)31607-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0003">
<span class="label">3.</span><cite>
Murillo Perez C. F., Harms M. H., Lindor K. D., et al., “Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase,” American Journal of Gastroenterology
115, no. 7 (2020): 1066–1074, 10.14309/ajg.0000000000000557.
</cite> [<a href="https://doi.org/10.14309/ajg.0000000000000557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32618657/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Gastroenterology&amp;title=Goals%20of%20Treatment%20for%20Improved%20Survival%20in%20Primary%20Biliary%20Cholangitis:%20Treatment%20Target%20Should%20be%20Bilirubin%20Within%20the%20Normal%20Range%20and%20Normalization%20of%20Alkaline%20Phosphatase&amp;author=C.%20F.%20Murillo%20Perez&amp;author=M.%20H.%20Harms&amp;author=K.%20D.%20Lindor&amp;volume=115&amp;issue=7&amp;publication_year=2020&amp;pages=1066-1074&amp;pmid=32618657&amp;doi=10.14309/ajg.0000000000000557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0004">
<span class="label">4.</span><cite>
Trivella J., John B. V., and Levy C., “Primary Biliary Cholangitis: Epidemiology, Prognosis, and Treatment,” Hepatology Communications
7, no. 6 (2023): e0179, 10.1097/hc9.0000000000000179.
</cite> [<a href="https://doi.org/10.1097/hc9.0000000000000179" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10241503/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37267215/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20Communications&amp;title=Primary%20Biliary%20Cholangitis:%20Epidemiology,%20Prognosis,%20and%20Treatment&amp;author=J.%20Trivella&amp;author=B.%20V.%20John&amp;author=C.%20Levy&amp;volume=7&amp;issue=6&amp;publication_year=2023&amp;pages=e0179&amp;pmid=37267215&amp;doi=10.1097/hc9.0000000000000179&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0005">
<span class="label">5.</span><cite>
European Association for the Study of the Liver
, “EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients With Primary Biliary Cholangitis,” Journal of Hepatology
67, no. 1 (2017): 145–172, 10.1016/j.jhep.2017.03.022.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2017.03.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28427765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hepatology&amp;title=EASL%20Clinical%20Practice%20Guidelines:%20The%20Diagnosis%20and%20Management%20of%20Patients%20With%20Primary%20Biliary%20Cholangitis&amp;volume=67&amp;issue=1&amp;publication_year=2017&amp;pages=145-172&amp;pmid=28427765&amp;doi=10.1016/j.jhep.2017.03.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0006">
<span class="label">6.</span><cite>
Lu M., Zhou Y., Haller I. V., et al., “Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment,” Clinical Gastroenterology and Hepatology
16, no. 8 (2018): 1342–1350.e1, 10.1016/j.cgh.2017.12.033.
</cite> [<a href="https://doi.org/10.1016/j.cgh.2017.12.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29277621/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Gastroenterology%20and%20Hepatology&amp;title=Increasing%20Prevalence%20of%20Primary%20Biliary%20Cholangitis%20and%20Reduced%20Mortality%20With%20Treatment&amp;author=M.%20Lu&amp;author=Y.%20Zhou&amp;author=I.%20V.%20Haller&amp;volume=16&amp;issue=8&amp;publication_year=2018&amp;pages=1342-1350.e1&amp;pmid=29277621&amp;doi=10.1016/j.cgh.2017.12.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0007">
<span class="label">7.</span><cite>
Levy C., Bowlus C. L., Carey E., et al., “A Real‐World Observational Cohort of Patients With Primary Biliary Cholangitis: TARGET‐Primary Biliary Cholangitis Study Design and Rationale,” Hepatology Communications
2, no. 5 (2018): 484–491, 10.1002/hep4.1173.
</cite> [<a href="https://doi.org/10.1002/hep4.1173" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5944592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29761165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20Communications&amp;title=A%20Real%E2%80%90World%20Observational%20Cohort%20of%20Patients%20With%20Primary%20Biliary%20Cholangitis:%20TARGET%E2%80%90Primary%20Biliary%20Cholangitis%20Study%20Design%20and%20Rationale&amp;author=C.%20Levy&amp;author=C.%20L.%20Bowlus&amp;author=E.%20Carey&amp;volume=2&amp;issue=5&amp;publication_year=2018&amp;pages=484-491&amp;pmid=29761165&amp;doi=10.1002/hep4.1173&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0008">
<span class="label">8.</span><cite>
Lindor K. D., Bowlus C. L., Boyer J., Levy C., and Mayo M., “Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases,” Hepatology
69, no. 1 (2019): 394–419, 10.1002/hep.30145.
</cite> [<a href="https://doi.org/10.1002/hep.30145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30070375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Primary%20Biliary%20Cholangitis:%202018%20Practice%20Guidance%20From%20the%20American%20Association%20for%20the%20Study%20of%20Liver%20Diseases&amp;author=K.%20D.%20Lindor&amp;author=C.%20L.%20Bowlus&amp;author=J.%20Boyer&amp;author=C.%20Levy&amp;author=M.%20Mayo&amp;volume=69&amp;issue=1&amp;publication_year=2019&amp;pages=394-419&amp;pmid=30070375&amp;doi=10.1002/hep.30145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0009">
<span class="label">9.</span><cite>
Düll M. M. and Kremer A. E., “Management of Chronic Hepatic Itch,” Dermatologic Clinics
36, no. 3 (2018): 293–300, 10.1016/j.det.2018.02.008.
</cite> [<a href="https://doi.org/10.1016/j.det.2018.02.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29929600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dermatologic%20Clinics&amp;title=Management%20of%20Chronic%20Hepatic%20Itch&amp;author=M.%20M.%20D%C3%BCll&amp;author=A.%20E.%20Kremer&amp;volume=36&amp;issue=3&amp;publication_year=2018&amp;pages=293-300&amp;pmid=29929600&amp;doi=10.1016/j.det.2018.02.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0010">
<span class="label">10.</span><cite>
Mayo M. J., Carey E., Smith H. T., et al., “Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients With Primary Biliary Cholangitis,” Digestive Diseases and Sciences
68, no. 3 (2023): 995–1005, 10.1007/s10620-022-07581-x.
</cite> [<a href="https://doi.org/10.1007/s10620-022-07581-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10406656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35704252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Digestive%20Diseases%20and%20Sciences&amp;title=Impact%20of%20Pruritus%20on%20Quality%20of%20Life%20and%20Current%20Treatment%20Patterns%20in%20Patients%20With%20Primary%20Biliary%20Cholangitis&amp;author=M.%20J.%20Mayo&amp;author=E.%20Carey&amp;author=H.%20T.%20Smith&amp;volume=68&amp;issue=3&amp;publication_year=2023&amp;pages=995-1005&amp;pmid=35704252&amp;doi=10.1007/s10620-022-07581-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0011">
<span class="label">11.</span><cite>
Trivedi H. D., Lizaola B., Tapper E. B., and Bonder A., “Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review,” American Journal of Medicine
130, no. 6 (2017): 744.e1–744.e7, 10.1016/j.amjmed.2017.01.037.</cite> [<a href="https://doi.org/10.1016/j.amjmed.2017.01.037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28238692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Medicine&amp;title=Management%20of%20Pruritus%20in%20Primary%20Biliary%20Cholangitis:%20A%20Narrative%20Review&amp;author=H.%20D.%20Trivedi&amp;author=B.%20Lizaola&amp;author=E.%20B.%20Tapper&amp;author=A.%20Bonder&amp;volume=130&amp;issue=6&amp;publication_year=2017&amp;pages=744.e1-744.e7&amp;pmid=28238692&amp;doi=10.1016/j.amjmed.2017.01.037&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0012">
<span class="label">12.</span><cite>
Hegade V. S., Bolier R., Oude Elferink R. P., Beuers U., Kendrick S., and Jones D. E., “A Systematic Approach to the Management of Cholestatic Pruritus in Primary Biliary Cirrhosis,” Frontline Gastroenterology
7, no. 3 (2016): 158–166, 10.1136/flgastro-2015-100618.
</cite> [<a href="https://doi.org/10.1136/flgastro-2015-100618" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5369477/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28839853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontline%20Gastroenterology&amp;title=A%20Systematic%20Approach%20to%20the%20Management%20of%20Cholestatic%20Pruritus%20in%20Primary%20Biliary%20Cirrhosis&amp;author=V.%20S.%20Hegade&amp;author=R.%20Bolier&amp;author=R.%20P.%20Oude%20Elferink&amp;author=U.%20Beuers&amp;author=S.%20Kendrick&amp;volume=7&amp;issue=3&amp;publication_year=2016&amp;pages=158-166&amp;pmid=28839853&amp;doi=10.1136/flgastro-2015-100618&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0013">
<span class="label">13.</span><cite>
Smith H. T., de Souza A. R., Thompson A. H., et al., “Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review,” Digestive Diseases and Sciences
68, no. 6 (2023): 2710–2730, 10.1007/s10620-023-07862-z.
</cite> [<a href="https://doi.org/10.1007/s10620-023-07862-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10024020/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36933112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Digestive%20Diseases%20and%20Sciences&amp;title=Cholestatic%20Pruritus%20Treatments%20in%20Primary%20Biliary%20Cholangitis%20and%20Primary%20Sclerosing%20Cholangitis:%20A%20Systematic%20Literature%20Review&amp;author=H.%20T.%20Smith&amp;author=A.%20R.%20de%20Souza&amp;author=A.%20H.%20Thompson&amp;volume=68&amp;issue=6&amp;publication_year=2023&amp;pages=2710-2730&amp;pmid=36933112&amp;doi=10.1007/s10620-023-07862-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0014">
<span class="label">14.</span><cite>
Kim H. P., Lieber S. R., Rogers M. E., et al., “A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis,” Hepatology Communications
4, no. 10 (2020): 1502–1515, 10.1002/hep4.1567.
</cite> [<a href="https://doi.org/10.1002/hep4.1567" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7527768/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33024919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20Communications&amp;title=A%20Systematic%20Review%20of%20Patient%E2%80%90Reported%20Outcomes%20in%20Primary%20Biliary%20Cholangitis%20and%20Primary%20Sclerosing%20Cholangitis&amp;author=H.%20P.%20Kim&amp;author=S.%20R.%20Lieber&amp;author=M.%20E.%20Rogers&amp;volume=4&amp;issue=10&amp;publication_year=2020&amp;pages=1502-1515&amp;pmid=33024919&amp;doi=10.1002/hep4.1567&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0015">
<span class="label">15.</span><cite>
Jacoby A., Rannard A., Buck D., et al., “Development, Validation, and Evaluation of the PBC‐40, a Disease Specific Health Related Quality of Life Measure for Primary Biliary Cirrhosis,” Gut
54, no. 11 (2005): 1622–1629, 10.1136/gut.2005.065862.
</cite> [<a href="https://doi.org/10.1136/gut.2005.065862" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1774759/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15961522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Development,%20Validation,%20and%20Evaluation%20of%20the%20PBC%E2%80%9040,%20a%20Disease%20Specific%20Health%20Related%20Quality%20of%20Life%20Measure%20for%20Primary%20Biliary%20Cirrhosis&amp;author=A.%20Jacoby&amp;author=A.%20Rannard&amp;author=D.%20Buck&amp;volume=54&amp;issue=11&amp;publication_year=2005&amp;pages=1622-1629&amp;pmid=15961522&amp;doi=10.1136/gut.2005.065862&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0016">
<span class="label">16.</span><cite>
Younossi Z. M., Stepanova M., Younossi I., and Racila A., “Validation of a Primary Biliary Cholangitis‐Specific Version of Chronic Liver Disease Questionnaire: CLDQ‐PBC,” Clinical and Translational Gastroenterology
15, no. 9 (2024): e1, 10.14309/ctg.0000000000000709.</cite> [<a href="https://doi.org/10.14309/ctg.0000000000000709" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11421712/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38738764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20and%20Translational%20Gastroenterology&amp;title=Validation%20of%20a%20Primary%20Biliary%20Cholangitis%E2%80%90Specific%20Version%20of%20Chronic%20Liver%20Disease%20Questionnaire:%20CLDQ%E2%80%90PBC&amp;author=Z.%20M.%20Younossi&amp;author=M.%20Stepanova&amp;author=I.%20Younossi&amp;author=A.%20Racila&amp;volume=15&amp;issue=9&amp;publication_year=2024&amp;pages=e1&amp;pmid=38738764&amp;doi=10.14309/ctg.0000000000000709&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0017">
<span class="label">17.</span><cite>
OCALIVA (Obeticholic Acid) Tablets [Package Insert] (Intercept Pharmaceuticals, Inc, 2022).</cite> [<a href="https://scholar.google.com/scholar_lookup?title=OCALIVA%20(Obeticholic%20Acid)%20Tablets%20%5BPackage%20Insert%5D&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0018">
<span class="label">18.</span><cite>
Food and Drug Administration (FDA)
, “FDA Drug Safety Communication: Due to Risk of Serious Liver Injury, FDA Restricts Use of Ocaliva (Obeticholic Acid) in Primary Biliary Cholangitis (PBC) Patients With Advanced Cirrhosis,” Adding and Updating Warnings. (2021), accessed April 27, 2025, <a href="https://www.fda.gov/media/149516/download?attachment" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/media/149516/download?attachment</a>.</cite>
</li>
<li id="liv70276-bib-0019">
<span class="label">19.</span><cite>
Food and Drug Administration (FDA)
, “FDA Drug Safety Communication: Serious Liver Injury Being Observed in Patients Without Cirrhosis Taking Ocaliva (Obeticholic Acid) to Treat Primary Biliary Cholangitis—Monitor Liver Tests Often for Early Identification of Worsening Liver Function,” (2024) accessed April 27, 2025, <a href="https://www.fda.gov/media/184316/download?attachment" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/media/184316/download?attachment</a>.</cite>
</li>
<li id="liv70276-bib-0020">
<span class="label">20.</span><cite>
Hirschfield G. M., Bowlus C. L., Mayo M. J., et al., “A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis,” New England Journal of Medicine
390, no. 9 (2024): 783–794, 10.1056/NEJMoa2312100.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2312100" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38381664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=A%20Phase%203%20Trial%20of%20Seladelpar%20in%20Primary%20Biliary%20Cholangitis&amp;author=G.%20M.%20Hirschfield&amp;author=C.%20L.%20Bowlus&amp;author=M.%20J.%20Mayo&amp;volume=390&amp;issue=9&amp;publication_year=2024&amp;pages=783-794&amp;pmid=38381664&amp;doi=10.1056/NEJMoa2312100&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0021">
<span class="label">21.</span><cite>
Pate J., Gutierrez J. A., Frenette C. T., et al., “Practical Strategies for Pruritus Management in the Obeticholic Acid‐Treated Patient With PBC: Proceedings From the 2018 Expert Panel,” BMJ Open Gastroenterology
6, no. 1 (2019): e000256, 10.1136/bmjgast-2018-000256.</cite> [<a href="https://doi.org/10.1136/bmjgast-2018-000256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6361341/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30815273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20Open%20Gastroenterology&amp;title=Practical%20Strategies%20for%20Pruritus%20Management%20in%20the%20Obeticholic%20Acid%E2%80%90Treated%20Patient%20With%20PBC:%20Proceedings%20From%20the%202018%20Expert%20Panel&amp;author=J.%20Pate&amp;author=J.%20A.%20Gutierrez&amp;author=C.%20T.%20Frenette&amp;volume=6&amp;issue=1&amp;publication_year=2019&amp;pages=e000256&amp;pmid=30815273&amp;doi=10.1136/bmjgast-2018-000256&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0022">
<span class="label">22.</span><cite>
Bowlus C. L., Kenney J. T., Rice G., and Navarro R., “Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update,” Journal of Managed Care &amp; Specialty Pharmacy
22, no. 10‐a‐s Suppl (2016): S3–S15, 10.18553/jmcp.2016.22.10-a-s.s3.</cite> [<a href="https://doi.org/10.18553/jmcp.2016.22.10-a-s.s3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10408407/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27700211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Managed%20Care%20&amp;%20Specialty%20Pharmacy&amp;title=Primary%20Biliary%20Cholangitis:%20Medical%20and%20Specialty%20Pharmacy%20Management%20Update&amp;author=C.%20L.%20Bowlus&amp;author=J.%20T.%20Kenney&amp;author=G.%20Rice&amp;author=R.%20Navarro&amp;volume=22&amp;issue=10%E2%80%90a%E2%80%90s%20Suppl&amp;publication_year=2016&amp;pages=S3-S15&amp;pmid=27700211&amp;doi=10.18553/jmcp.2016.22.10-a-s.s3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0023">
<span class="label">23.</span><cite>
D'Amato D., De Vincentis A., Malinverno F., et al., “Real‐World Experience With Obeticholic Acid in Patients With Primary Biliary Cholangitis,” JHEP Reports
3, no. 2 (2021): 100248, 10.1016/j.jhepr.2021.100248.
</cite> [<a href="https://doi.org/10.1016/j.jhepr.2021.100248" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7930359/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33681748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JHEP%20Reports&amp;title=Real%E2%80%90World%20Experience%20With%20Obeticholic%20Acid%20in%20Patients%20With%20Primary%20Biliary%20Cholangitis&amp;author=D.%20D'Amato&amp;author=A.%20De%20Vincentis&amp;author=F.%20Malinverno&amp;volume=3&amp;issue=2&amp;publication_year=2021&amp;pages=100248&amp;pmid=33681748&amp;doi=10.1016/j.jhepr.2021.100248&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0024">
<span class="label">24.</span><cite>
Gomez E., Garcia Buey L., Molina E., et al., “Effectiveness and Safety of Obeticholic Acid in a Southern European Multicentre Cohort of Patients With Primary Biliary Cholangitis and Suboptimal Response to Ursodeoxycholic Acid,” Alimentary Pharmacology &amp; Therapeutics
53, no. 4 (2021): 519–530, 10.1111/apt.16181.
</cite> [<a href="https://doi.org/10.1111/apt.16181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33314220/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alimentary%20Pharmacology%20&amp;%20Therapeutics&amp;title=Effectiveness%20and%20Safety%20of%20Obeticholic%20Acid%20in%20a%20Southern%20European%20Multicentre%20Cohort%20of%20Patients%20With%20Primary%20Biliary%20Cholangitis%20and%20Suboptimal%20Response%20to%20Ursodeoxycholic%20Acid&amp;author=E.%20Gomez&amp;author=L.%20Garcia%20Buey&amp;author=E.%20Molina&amp;volume=53&amp;issue=4&amp;publication_year=2021&amp;pages=519-530&amp;pmid=33314220&amp;doi=10.1111/apt.16181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0025">
<span class="label">25.</span><cite>
Roberts S. B., Ismail M., Kanagalingam G., et al., “Real‐World Effectiveness of Obeticholic Acid in Patients With Primary Biliary Cholangitis,” Hepatology Communications
4, no. 9 (2020): 1332–1345, 10.1002/hep4.1518.
</cite> [<a href="https://doi.org/10.1002/hep4.1518" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7471421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32923836/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20Communications&amp;title=Real%E2%80%90World%20Effectiveness%20of%20Obeticholic%20Acid%20in%20Patients%20With%20Primary%20Biliary%20Cholangitis&amp;author=S.%20B.%20Roberts&amp;author=M.%20Ismail&amp;author=G.%20Kanagalingam&amp;volume=4&amp;issue=9&amp;publication_year=2020&amp;pages=1332-1345&amp;pmid=32923836&amp;doi=10.1002/hep4.1518&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0026">
<span class="label">26.</span><cite>
Hegade V. S., Mells G. F., Fisher H., et al., “Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom,” Clinical Gastroenterology and Hepatology
17, no. 7 (2019): 1379–1387.e3, 10.1016/j.cgh.2018.12.007.
</cite> [<a href="https://doi.org/10.1016/j.cgh.2018.12.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30557739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Gastroenterology%20and%20Hepatology&amp;title=Pruritus%20Is%20Common%20and%20Undertreated%20in%20Patients%20With%20Primary%20Biliary%20Cholangitis%20in%20the%20United%20Kingdom&amp;author=V.%20S.%20Hegade&amp;author=G.%20F.%20Mells&amp;author=H.%20Fisher&amp;volume=17&amp;issue=7&amp;publication_year=2019&amp;pages=1379-1387.e3&amp;pmid=30557739&amp;doi=10.1016/j.cgh.2018.12.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0027">
<span class="label">27.</span><cite>
Phan N. Q., Blome C., Fritz F., et al., “Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients With Chronic Pruritus,” Acta Dermato‐Venereologica
92, no. 5 (2012): 502–507, 10.2340/00015555-1246.
</cite> [<a href="https://doi.org/10.2340/00015555-1246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22170091/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Dermato%E2%80%90Venereologica&amp;title=Assessment%20of%20Pruritus%20Intensity:%20Prospective%20Study%20on%20Validity%20and%20Reliability%20of%20the%20Visual%20Analogue%20Scale,%20Numerical%20Rating%20Scale%20and%20Verbal%20Rating%20Scale%20in%20471%20Patients%20With%20Chronic%20Pruritus&amp;author=N.%20Q.%20Phan&amp;author=C.%20Blome&amp;author=F.%20Fritz&amp;volume=92&amp;issue=5&amp;publication_year=2012&amp;pages=502-507&amp;pmid=22170091&amp;doi=10.2340/00015555-1246&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0028">
<span class="label">28.</span><cite>
CymaBay Therapeutics, Inc
., “Data on file. CB8025‐32251 Clinical Study Protocol. A 52‐Week, Double‐Blind, Placebo‐Controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA),” (2024), IDEAL, Version 2.0, accessed August 5, 2024.</cite>
</li>
<li id="liv70276-bib-0029">
<span class="label">29.</span><cite>
Elman S., Hynan L. S., Gabriel V., and Mayo M. J., “The 5‐D Itch Scale: A New Measure of Pruritus,” British Journal of Dermatology
162, no. 3 (2010): 587–593, 10.1111/j.1365-2133.2009.09586.x.
</cite> [<a href="https://doi.org/10.1111/j.1365-2133.2009.09586.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2875190/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19995367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Dermatology&amp;title=The%205%E2%80%90D%20Itch%20Scale:%20A%20New%20Measure%20of%20Pruritus&amp;author=S.%20Elman&amp;author=L.%20S.%20Hynan&amp;author=V.%20Gabriel&amp;author=M.%20J.%20Mayo&amp;volume=162&amp;issue=3&amp;publication_year=2010&amp;pages=587-593&amp;pmid=19995367&amp;doi=10.1111/j.1365-2133.2009.09586.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0030">
<span class="label">30.</span><cite>
van Reenen M. and Janssen B., EQ‐5D‐5L User Guide: Basic Information on How to Use the EQ‐5D‐5L Instrument (EuroQol Research Foundation, 2015).</cite> [<a href="https://scholar.google.com/scholar_lookup?title=EQ%E2%80%905D%E2%80%905L%20User%20Guide:%20Basic%20Information%20on%20How%20to%20Use%20the%20EQ%E2%80%905D%E2%80%905L%20Instrument&amp;author=M.%20van%20Reenen&amp;author=B.%20Janssen&amp;publication_year=2015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0031">
<span class="label">31.</span><cite>
FACIT.org
, “Functional Assessment of Chronic Illness Therapy—Fatigue Scale”, <a href="https://www.facit.org/measures/facit-fatigue" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.facit.org/measures/facit‐fatigue</a>.</cite>
</li>
<li id="liv70276-bib-0032">
<span class="label">32.</span><cite>
Reilly Associates Health Outcomes Research
, <a href="http://www.reillyassociates.net" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.reillyassociates.net</a>.</cite>
</li>
<li id="liv70276-bib-0033">
<span class="label">33.</span><cite>
Reilly M. C., Bracco A., Ricci J. F., Santoro J., and Stevens T., “The Validity and Accuracy of the Work Productivity and Activity Impairment Questionnaire—Irritable Bowel Syndrome Version (WPAI:IBS),” Alimentary Pharmacology and Therapeutics
20, no. 4 (2004): 459–467, 10.1111/j.1365-2036.2004.02091.x.
</cite> [<a href="https://doi.org/10.1111/j.1365-2036.2004.02091.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15298641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alimentary%20Pharmacology%20and%20Therapeutics&amp;title=The%20Validity%20and%20Accuracy%20of%20the%20Work%20Productivity%20and%20Activity%20Impairment%20Questionnaire%E2%80%94Irritable%20Bowel%20Syndrome%20Version%20(WPAI:IBS)&amp;author=M.%20C.%20Reilly&amp;author=A.%20Bracco&amp;author=J.%20F.%20Ricci&amp;author=J.%20Santoro&amp;author=T.%20Stevens&amp;volume=20&amp;issue=4&amp;publication_year=2004&amp;pages=459-467&amp;pmid=15298641&amp;doi=10.1111/j.1365-2036.2004.02091.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0034">
<span class="label">34.</span><cite>
Reilly M. C., Zbrozek A. S., and Dukes E. M., “The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument,” PharmacoEconomics
4, no. 5 (1993): 353–365, 10.2165/00019053-199304050-00006.
</cite> [<a href="https://doi.org/10.2165/00019053-199304050-00006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10146874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PharmacoEconomics&amp;title=The%20Validity%20and%20Reproducibility%20of%20a%20Work%20Productivity%20and%20Activity%20Impairment%20Instrument&amp;author=M.%20C.%20Reilly&amp;author=A.%20S.%20Zbrozek&amp;author=E.%20M.%20Dukes&amp;volume=4&amp;issue=5&amp;publication_year=1993&amp;pages=353-365&amp;pmid=10146874&amp;doi=10.2165/00019053-199304050-00006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0035">
<span class="label">35.</span><cite>
Castellanos‐Fernández M. I., Borges‐González S. A., Stepanova M., et al., “Health‐Related Quality of Life in Cuban Patients With Chronic Liver Disease: A Real‐World Experience,” Annals of Hepatology
22 (2021): 100277, 10.1016/j.aohep.2020.10.005.
</cite> [<a href="https://doi.org/10.1016/j.aohep.2020.10.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33130334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Hepatology&amp;title=Health%E2%80%90Related%20Quality%20of%20Life%20in%20Cuban%20Patients%20With%20Chronic%20Liver%20Disease:%20A%20Real%E2%80%90World%20Experience&amp;author=M.%20I.%20Castellanos%E2%80%90Fern%C3%A1ndez&amp;author=S.%20A.%20Borges%E2%80%90Gonz%C3%A1lez&amp;author=M.%20Stepanova&amp;volume=22&amp;publication_year=2021&amp;pages=100277&amp;pmid=33130334&amp;doi=10.1016/j.aohep.2020.10.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0036">
<span class="label">36.</span><cite>
Chandrakumar D., Arumugam V., and Vasudevan A., “Exploring Presenteeism Trends: A Comprehensive Bibliometric and Content Analysis,” Frontiers in Psychology
15 (2024): 1352602, 10.3389/fpsyg.2024.1352602.
</cite> [<a href="https://doi.org/10.3389/fpsyg.2024.1352602" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11144874/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38831942/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Psychology&amp;title=Exploring%20Presenteeism%20Trends:%20A%20Comprehensive%20Bibliometric%20and%20Content%20Analysis&amp;author=D.%20Chandrakumar&amp;author=V.%20Arumugam&amp;author=A.%20Vasudevan&amp;volume=15&amp;publication_year=2024&amp;pages=1352602&amp;pmid=38831942&amp;doi=10.3389/fpsyg.2024.1352602&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0037">
<span class="label">37.</span><cite>
Shuster A., O'Brien M., Luo Y., et al., “Emotional Adaptation During a Crisis: Decline in Anxiety and Depression After the Initial Weeks of COVID‐19 in the United States,” Translational Psychiatry
11, no. 1 (2021): 435, 10.1038/s41398-021-01552-y.
</cite> [<a href="https://doi.org/10.1038/s41398-021-01552-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8377451/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34417441/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Translational%20Psychiatry&amp;title=Emotional%20Adaptation%20During%20a%20Crisis:%20Decline%20in%20Anxiety%20and%20Depression%20After%20the%20Initial%20Weeks%20of%20COVID%E2%80%9019%20in%20the%20United%20States&amp;author=A.%20Shuster&amp;author=M.%20O'Brien&amp;author=Y.%20Luo&amp;volume=11&amp;issue=1&amp;publication_year=2021&amp;pages=435&amp;pmid=34417441&amp;doi=10.1038/s41398-021-01552-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0038">
<span class="label">38.</span><cite>
Turco M., Cazzagon N., Franceschet I., et al., “Morning Bright Light Treatment for Sleep‐Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study,” Frontiers in Physiology
9 (2018): 1530, 10.3389/fphys.2018.01530.
</cite> [<a href="https://doi.org/10.3389/fphys.2018.01530" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6230563/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30455647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Physiology&amp;title=Morning%20Bright%20Light%20Treatment%20for%20Sleep%E2%80%90Wake%20Disturbances%20in%20Primary%20Biliary%20Cholangitis:%20A%20Pilot%20Study&amp;author=M.%20Turco&amp;author=N.%20Cazzagon&amp;author=I.%20Franceschet&amp;volume=9&amp;publication_year=2018&amp;pages=1530&amp;pmid=30455647&amp;doi=10.3389/fphys.2018.01530&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0039">
<span class="label">39.</span><cite>
Lindor K. D., Bowlus C. L., Boyer J., Levy C., and Mayo M., “Primary Biliary Cholangitis: 2021 Practice Guidance Update From the American Association for the Study of Liver Diseases,” Hepatology
75, no. 4 (2022): 1012–1013, 10.1002/hep.32117.
</cite> [<a href="https://doi.org/10.1002/hep.32117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34431119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Primary%20Biliary%20Cholangitis:%202021%20Practice%20Guidance%20Update%20From%20the%20American%20Association%20for%20the%20Study%20of%20Liver%20Diseases&amp;author=K.%20D.%20Lindor&amp;author=C.%20L.%20Bowlus&amp;author=J.%20Boyer&amp;author=C.%20Levy&amp;author=M.%20Mayo&amp;volume=75&amp;issue=4&amp;publication_year=2022&amp;pages=1012-1013&amp;pmid=34431119&amp;doi=10.1002/hep.32117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0040">
<span class="label">40.</span><cite>
Kremer A. E., van Dijk R., Leckie P., et al., “Serum Autotaxin Is Increased in Pruritus of Cholestasis, but Not of Other Origin, and Responds to Therapeutic Interventions,” Hepatology
56, no. 4 (2012): 1391–1400, 10.1002/hep.25748.
</cite> [<a href="https://doi.org/10.1002/hep.25748" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22473838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Serum%20Autotaxin%20Is%20Increased%20in%20Pruritus%20of%20Cholestasis,%20but%20Not%20of%20Other%20Origin,%20and%20Responds%20to%20Therapeutic%20Interventions&amp;author=A.%20E.%20Kremer&amp;author=R.%20van%20Dijk&amp;author=P.%20Leckie&amp;volume=56&amp;issue=4&amp;publication_year=2012&amp;pages=1391-1400&amp;pmid=22473838&amp;doi=10.1002/hep.25748&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70276-bib-0041">
<span class="label">41.</span><cite>
Kremer A. E., Mayo M. J., Hirschfield G. M., et al., “Seladelpar Treatment Reduces IL‐31 and Pruritus in Patients With Primary Biliary Cholangitis,” Hepatology
80, no. 1 (2024): 27–37, 10.1097/hep.0000000000000728.
</cite> [<a href="https://doi.org/10.1097/hep.0000000000000728" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11191048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38117036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Seladelpar%20Treatment%20Reduces%20IL%E2%80%9031%20and%20Pruritus%20in%20Patients%20With%20Primary%20Biliary%20Cholangitis&amp;author=A.%20E.%20Kremer&amp;author=M.%20J.%20Mayo&amp;author=G.%20M.%20Hirschfield&amp;volume=80&amp;issue=1&amp;publication_year=2024&amp;pages=27-37&amp;pmid=38117036&amp;doi=10.1097/hep.0000000000000728&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
<strong>Figure S1:</strong> PRO outcomes by group based on regression analysis: no/mild pruritus (NMP) vs moderate/severe pruritus (MSP).</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374225/bin/LIV-45-0-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">LIV-45-0-s001.docx</a><sup> (5.8MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Liver International are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1111/liv.70276"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/LIV-45-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (429.4 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374225/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374225/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374225%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374225/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374225/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374225/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40847640/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374225/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40847640/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374225/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374225/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="wOUZA2JbpQIpaXv5tc3EUB4W11dExuv8pOXPajXQPSOWMaR9wnlKfsoOVAghaPli">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
